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ABSTRACT 
 
 
Patients with renal failure undergoing maintenance hemodialysis (MHD) therapy suffer 
from a number of co-morbidities including skeletal muscle loss, reduced physical function, a 
significantly increased fall risk, and reduced quality of life (QOL).  Therefore, interventions to 
combat these co-morbidities are needed.  Beta-hydroxy-beta-methylbutyrate (HMB) is a 
metabolite of the amino acid leucine that has been shown to improve lean mass and physical 
function in the elderly and clinical populations, but had not previously been studied in MHD 
patients.  Approximately 25 percent of supplemental HMB is cleared by the kidney; therefore, 
we first performed an acute study to determine the clearance of supplemental HMB in 
hemodialysis patients.  MHD patients (n=8) consumed 3g HMB prior to a standard hemodialysis 
session.  Following supplementation with HMB, a majority of supplemental HMB was cleared 
within 48hrs and plasma HMB levels returned to baseline within 7 days in all participants.  
These results suggest that supplemental HMB is cleared in patients with impaired renal function.   
Based upon these results, we performed a double blind, placebo controlled, randomized 
trial to assess the effects of daily HMB supplementation on co-morbidities in MHD patients.  
MHD patients were recruited and assigned to either daily supplementation with HMB (n=16) or 
placebo (n=17) for 6 months.  No significant effects of HMB on lean mass, strength, physical 
function, fall risk, or quality of life were found using an intent-to-treat analysis.  However, upon 
analysis of plasma HMB concentrations, 5 of 16 patients (31%) who completed the study in the 
HMB group were found to be non-compliant at 3 or 6 months.  Therefore, we performed a per-
protocol analysis with compliant participants only.  Although this analysis was underpowered, 
we observed a trend for improvements in chair stand and timed up-and-go tests with HMB 
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supplementation.  However, no effects of HMB were observed for lean mass, strength, fall risk, 
or quality of life.  As a whole, these results do not support the efficacy of HMB to attenuate 
muscle loss and declines in physical function in MHD patients.  However, the observed low-
compliance with study pills may have affected results.  Moreover, it highlights the need for 
future interventions targeted at reducing pill burden and improving pill compliance in this 
population. 
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CHAPTER 1 
INTRODUCTION 
 
The number of patients with renal failure requiring maintenance hemodialysis (MHD) 
treatment is expected to double within the next 30 years, primarily due to the increasing rates of 
hypertension and diabetes [1].  Once on hemodialysis, patients experience a number of a co-
morbidities including skeletal muscle wasting, which has been shown to be a strong predictor of 
mortality in this population [2-4].  In addition, this decline in skeletal muscle mass contributes to 
reductions in physical function [5], a significantly increased fall risk [6], and reduced quality of 
life (QOL) [7].  Pharmacological agents have been investigated to treat muscle loss in dialysis 
patients; however, many of these treatments are expensive and have undesirable side effects [8, 
9].  As a result, low-cost interventions designed to attenuate declines in muscle mass are needed 
in this critically ill patient population.   
Beta-hydroxy beta-methylbutyrate (HMB) represents a potential low-cost nutritional 
intervention to attenuate muscle loss in hemodialysis patients.  HMB is a metabolite of the amino 
acid leucine that has been shown to safely attenuate muscle mass loss in other clinical 
populations with accelerated muscle loss, such as the elderly [10], cancer [11], and AIDS  
patients [12], primarily through reductions in skeletal muscle protein catabolism (as reviewed by 
[13]).  A recent study examining the effects of 4 weeks of HMB supplementation in diabetic 
hemodialysis patients observed beneficial effects on wound healing [14]; however, lean mass, 
strength, physical function, and quality of life were not measured.  Therefore, the primary 
purpose of this trial is to determine if oral supplementation with HMB attenuates muscle loss and 
declines in muscle strength and physical function in hemodialysis patients. 
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CHAPTER 2 
LITERATURE REVIEW: MUSCLE LOSS IN HEMODIALYSIS PATIENTS 
 
Chronic kidney disease 
 Chronic kidney disease (CKD) affects 13 percent of adults in the United States and the 
prevalence is increasing rapidly [15].  The severity of CKD is determined by glomerular 
filtration rate (GFR), a measure of creatinine clearance.  A GFR of less than 15 mg/min/1.73m 
represents end stage renal disease (ESRD) at which point a patient must receive dialysis for the 
remainder of their life, unless a kidney transplant is received.  However, the number of patients 
in need of a kidney transplant far exceeds the number of kidney donors, resulting in more than  
350,000 patients currently on hemodialysis in the United States [16].  Moreover, the number of 
hemodialysis patients is increasing and expected to double within the next 30 years, primarily 
due to the increasing rates of hypertension and diabetes, the leading causes of CKD in the United 
States [1]. 
 Once on hemodialysis, patients experience a number of a co-morbidities including 
skeletal muscle wasting [2] which results in reduced physical function [5] and an increased fall 
risk [6].  Due to these co-morbities, hemodialysis patients are typically less active than sedentary 
healthy adults [17] and have a reduced quality of life [7].  Moreover, approximately 2/3 of 
hemodialysis patients will die within 5 years of initiation of hemodialysis [18] and this extremely 
high mortality rate has not improved in the last two decades [19].  This suggests that alternative 
therapies to attenuate declines in skeletal muscle mass, physical function, and quality of life in 
hemodialysis patients are needed.    
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Skeletal muscle loss: prevalence and association with mortality 
 Protein Energy Wasting (PEW), defined as “a state of decreased body stores of protein 
and energy fuels that is often associated with diminished functional capacity related to metabolic 
stress,” is a common co-morbidity in hemodialysis patients [20].  Due to the high prevalence of 
PEW, incident MHD patients lose approximately 1-3 kg lean mass annually resulting in a low 
skeletal muscle mass in many hemodialysis patients [2].  Indeed, Carrero et al. [21] reported at 
least some degree of atrophy in 39% of a cohort of hemodialysis patients and a skeletal muscle 
mass of less than 90% of predicted was observed in 62% of dialysis patients in a French cohort 
[22].  Likewise, MacDonald et al. [23] observed a reduced appendicular lean mass in a cohort of 
hemodialysis patients, as compared with age-matched healthy controls.   
Skeletal muscle mass also has been correlated with mortality in this population.  Several 
studies have shown a correlation between mortality and a low skeletal muscle mass, measured by 
creatinine levels [3, 4, 24, 25], mid-arm circumference [26, 27], or DXA [28].  Moreover, 
skeletal muscle loss, measured by reductions in blood creatinine levels, has been shown to be a 
strong predictor of mortality in this population [3, 4].  Although skeletal muscle loss is not the 
primary cause of death in this population, the relationship between skeletal muscle loss and 
mortality is hypothesized to exist because skeletal muscle loss may increase risk of death from 
cardiovascular disease and infection, the leading causes of death in this population [29].  Taken 
together, these data suggest that skeletal muscle loss is a significant problem in hemodialysis 
patients and interventions are needed to combat this prevalent co-morbidity.  
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Causes of skeletal muscle loss in hemodialysis patients 
 Skeletal muscle loss is a common comorbidity in hemodialysis patients.  Rates of muscle 
loss as high as 1-3 kg annually have been observed in incident MHD patients [2].  Dialysis 
patients experience skeletal muscle loss for several reasons including: metabolic acidosis, 
inflammation, insulin resistance, decreased nutrient intake, hormonal abnormalities, an elevated 
metabolic rate, and loss of amino acids into the dialysate (as reviewed by [30, 31]).  Moreover, 
the dialysis process has been shown to up-regulate expression of genes involved in skeletal 
muscle protein degradation and result in a breakdown of skeletal muscle proteins [32].  The 
following section will review the causes of skeletal muscle loss in hemodialysis patients. 
 In end-stage renal disease patients, metabolic acidosis is caused by reduced bicarbonate 
production in the kidney, resulting in an inability to neutralize blood pH.  Acidosis in 
hemodialysis patients has been shown to stimulate skeletal muscle protein degradation and result 
in a negative nitrogen balance [33, 34].  The mechanism by which metabolic acidosis stimulates 
protein degradation is not completely understood, but may involve impairment of insulin 
signaling [35], reduction in sodium coupled neutral amino acid transporter 2 (SNAT2) activity 
resulting in decreased amino acid transport into skeletal muscle cells [36], and/or up-regulation 
of the ubiquitin-proteasome pathway in skeletal muscle [37].  Correction of metabolic acidosis 
with bicarbonate has been shown to decrease protein degradation and amino acid oxidation [33, 
34], increase intramuscular concentration of branched chain amino acids [38], and increase 
bodyweight and mid-arm muscle circumference in  hemodialysis patients [39].  Thus, metabolic 
acidosis represents one of many causes of muscle loss in hemodialysis patients.   
 Elevated inflammation is common in dialysis patients and contributes to skeletal muscle 
loss.  Several studies have shown that dialysis patients have increased levels of interleukin-6 (IL-
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6) [40-44], tumor necrosis factor alpha (TNF-α) [41, 42] and C-reactive protein (CRP) [41, 44] 
compared with healthy controls.  Inflammation in dialysis patients is caused by many factors 
including: increased oxidative stress, decreased clearance of pro-inflammatory cytokines, bio-
incompatibility of dialysis membranes, impurities in dialysis water and dialysate, and back-
filtration of contaminants during dialysis (as reviewed by [45]).  In addition, the hemodialysis 
process has been shown to increase levels of plasma IL-6 [40-42, 46] which is believed to 
originate from either peripheral blood mononuclear cells [47] and/or skeletal muscle [44].  
Moreover, the increase in IL-6 during a hemodialysis session has been correlated with an up-
regulation of genes associated with skeletal muscle protein catabolism [42] and an increased rate 
of skeletal muscle protein degradation [46, 48].  The amino acids released from skeletal muscle 
during the hemodialysis process are believed to participate in acute-phase protein synthesis in the 
liver, which is elevated during hemodialysis [41].  In addition to correlations with protein 
catabolism and acute-phase protein synthesis during hemodialysis, inflammatory cytokine 
concentration has also been correlated with skeletal muscle mass in this population.  Indeed, 
Kaizu et al. [43] showed that levels of IL-6 and CRP were inversely correlated with thigh muscle 
area, as measured by computer topography (CT), in hemodialysis patients.  Taken together, these 
findings suggest that elevated inflammation in hemodialysis patients is, at least in part, 
responsible for the increase in skeletal muscle loss in this population. 
 Insulin resistance in hemodialysis patients occurs for several reasons including: metabolic 
acidosis, elevated inflammation, increased oxidative stress, accumulation of uremic toxins, 
excessive body fat, vitamin D deficiency and reduced physical activity (as reviewed by [49]).   
Insulin prevents skeletal muscle loss primarily through inhibition of catabolic pathways in 
skeletal muscle [50].  Indeed, Pupim et al. [51] observed an increased rate of skeletal muscle 
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protein degradation in diabetic hemodialysis patients compared with non-diabetic patients.  This 
increase in protein degradation resulted in a significantly greater loss of skeletal muscle mass in 
diabetic hemodialysis patients.  In a 1 year observational study of incident MHD patients, non-
diabetic hemodialysis patients lost 1.1 kg lean mass while diabetic hemodialysis patients lost 3.4 
kg lean mass [2].  Moreover, in non-diabetic non-obese hemodialysis patients, insulin resistance 
is evident and inversely correlated with net balance of skeletal muscle protein turnover [52].  
Therefore, insulin resistance may be contributing to skeletal muscle loss in both diabetic and 
non-diabetic hemodialysis patients. 
 Anorexia is present in 35-50 percent of hemodialysis patients and results in a reduced 
nutrient intake [53].  In a cohort of 1,901 adults receiving hemodialysis in the United States, 
average caloric and protein intakes of 23.2 kcal/kg bodyweight/day and 0.96 g protein/kg 
bodyweight/day, respectively, have been reported [54].  This level of calorie and protein intake is 
well below the Kidney Disease Outcomes Quality Initiative (KDOQI) recommendation of 35 
kcal/kg bodyweight/day and 1.2 g protein/kg bodyweight/day for hemodialysis patients [55]. 
Moreover, calorie and protein intakes are significantly lower on days in which patients undergo 
hemodialysis treatment [54] and are reduced the longer a patient is on hemodialysis [56].  
Reduced caloric intake in hemodialysis patients occurs for several reasons including: dry mouth 
[57], changes in taste and smell [58], dental problems [59], and altered GI function [60].  
Additionally, elevated inflammation has been shown to decrease appetite.  Significant negative 
correlations between appetite and inflammatory markers, IL-6 and CRP, have been observed in 
hemodialysis patients [61, 62].  Moreover, abnormalities in appetite regulating hormones are also 
common.  Elevated levels of deacyl-ghrelin [63] and leptin [64] are present in dialysis patients 
and have been correlated with a reduced skeletal muscle mass in this population [65, 66].   
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Dietary restrictions may also be, in part, responsible for the reduced caloric intake.  In the 
United States, dialysis patients are placed on a restrictive diet which may leave patients feeling 
limited on food selection [67].  Furthermore, patients are not allowed to eat during hemodialysis, 
a period in which skeletal muscle protein catabolism peaks [68].  Finally, dietary counseling to 
lower protein intake during earlier stages of CKD may contribute to an insufficient protein intake 
after dialysis initiation [69].  For all of the aforementioned reasons, a reduced nutrient intake is 
common in hemodialysis patients and contributes to skeletal muscle loss in this population. 
 In addition to abnormalities in appetite regulating hormones, several other hormone 
systems are dysregulated in hemodialysis patients and may contribute to skeletal muscle loss.  
Cortisol increases during hemodialysis [70] and is correlated with proteolysis [71].  Cortisol may 
contribute to skeletal muscle loss, in part, through inhibition of insulin signaling [72].  In 
addition, adrenalectomy studies in rodent models of CKD have shown that glucocorticoids are 
necessary for metabolic acidosis induced skeletal muscle degradation [73].  Furthermore, in 
humans, hypercortisolemia has been shown to blunt the anabolic response to amino acids [74].  
Taken together, these results indicate that cortisol may increase skeletal muscle loss through a 
variety of mechanisms.  Testosterone production and metabolism are also dysregulated in male 
dialysis patients and correlated with a reduced muscle mass in this population [75, 76].  
Moreover, Carrero et al. [76] observed an increased risk of all-cause mortality in male 
hemodialysis patients with low serum testosterone levels even after adjustment for age, sex 
hormone binding globulin, cardiovascular disease, diabetes and inflammation.  However, this 
relationship was lost after adjustment for muscle mass, as measured by serum creatinine, 
suggesting that testosterone levels are related to muscle wasting and subsequent mortality risk in 
this population. In addition, vitamin D is reduced in hemodialysis due to a decreased production 
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of 1, 25-dihydroxyvitamin D3, the active form of vitamin D, in the kidney.  Vitamin D may play 
a role in insulin sensitivity in hemodialysis patients.  Indeed, Mak et al. [77] supplemented 
hemodialysis patients with intravenous 1,25-dihydroxyvitamin D3 for 4 weeks and observed an 
increase in insulin sensitivity, as measured by euglycemic clamp technique.  Taken together, 
these studies suggest that endocrine abnormalities may contribute to skeletal muscle loss in 
hemodialysis patients. 
 Hemodialysis patients have an increased resting energy expenditure (REE) which may 
contribute to a negative energy balance and skeletal muscle loss.  Indeed, an increased REE has 
been shown in dialysis [78] and pre-dialysis [79] patients compared to age and BMI matched 
healthy controls.  Moreover, REE increases during a hemodialysis session [78].  The mechanism 
for the elevated REE in dialysis patients is not completely understood; however, inflammation 
has been shown to be positively correlated with REE in both dialysis [80] and pre-dialysis 
patients [81].  Therefore, elevated inflammation in dialysis patients may lead to increases in REE 
which may further contribute to a negative energy balance and decrease skeletal muscle mass in 
this population. 
 Plasma amino acid loss during the hemodialysis process contributes to skeletal muscle 
loss in this population.  Ikizler et at. [82] observed a 6-8g loss in amino acids through the dialysis 
membrane during a hemodialysis session.  This loss is equivalent to an approximately 2 kg loss 
annually in patients undergoing thrice weekly hemodialysis [32] and is similar to annual changes 
in lean mass that have been observed in this population [2].  Thus, intradialytic amino acid loss 
represents yet another mechanism by which skeletal muscle is lost in hemodialysis patients.  
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Molecular mechanisms of proteolysis in skeletal muscle of hemodialysis patients 
Skeletal muscle protein turnover is the product of skeletal muscle protein synthesis and 
skeletal muscle protein degradation.  When synthesis exceeds degradation, there is a net 
synthesis of skeletal muscle protein.  However, when degradation exceeds synthesis, there is a 
net breakdown of skeletal muscle protein.  The hemodialysis process has been shown to increase 
skeletal muscle protein degradation, without an adequate increase in protein synthesis, resulting 
in a negative net balance of skeletal muscle protein turnover [70].  Moreover, several signaling 
pathways involved in skeletal muscle protein turnover are differentially expressed in 
hemodialysis patients compared with healthy adults (Figure 1).  This section will review 
abnormalities in skeletal muscle signaling pathways involved in protein synthesis and 
degradation in hemodialysis patients.   
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↑ Inflammation
↑ Oxidative Stress 
↑ Acidosis
↑ MURF-1 
↑ Atrogen1
↑ NF-KB
↑ Protein 
Degradation
↑ Apoptosis
↑ Caspase-3
↓ mTOR
↓ AKT
↓ PI3K
↓ S6K
↓ Amino 
Acids 
(Leucine)
↓ 4EBP1
↓ Protein 
Synthesis
↓ IGF-1↑ Myostatin
↑ FOXO-1
↓ Myo D
↓ Myogenesis
 
Figure 1. Anabolic and catabolic pathways in skeletal muscle of patients with chronic kidney 
disease.  Arrows represent an increase or decrease in a protein or pathway compared with healthy 
adults.  Increased inflammation, oxidative stress, and metabolic acidosis stimulate protein 
degradation and apoptosis through activation of caspase and ubiquitin-proteasome pathways.  
Elevated myostatin inhibits myogenesis and protein synthesis.  Reduced IGF-1 lowers protein 
synthesis and myogenesis and increases protein degradation.  Reduced amino acid intake lowers 
protein synthesis.  Abbreviations: NF-ΚB – nuclear factor –KB;  MURF-1 – muscle ring finger-
1; IGF-1 – insulin like growth factor-1; IRS-1 – insulin receptor substrate-1; mTOR – 
mammalian target of rapamycin; 4EBP1 – eukaryotic initiation factor 4E binding protein-1; S6K 
– ribosomal S6 kinase; MyoD – myoblast determination protein 1; FOXO-1 – forkhead box O1. 
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 The insulin-like growth factor-1 (IGF-1) pathway is the primary anabolic pathway in 
skeletal muscle tissue.  Binding of IGF-1 to the IGF-1 receptor activates in a signaling cascade 
that results in the phosphorylation of Akt and the mammalian target of rapamycin (mTOR), 
ultimately, stimulating protein synthesis (as reviewed by [83]).  However, in the skeletal muscle 
of hemodialysis patients, IGF-1 mRNA [84-86] and protein [23, 86] are reduced.  Likewise, in 
animal models of CKD reduced intramuscular IGF-1 has also been observed [87-89].  In addition 
to a reduced quantity of intramuscular IGF-1, IGF-1 resistance may be present in CKD.  In an 
animal model, Zhang et al. [90] injected IGF-1 into the skeletal muscle of CKD and wild-type 
rats.  Reduced Akt phosphorylation was observed in the skeletal muscle of CKD rats after IGF-1 
injection, suggesting possible IGF-1 resistance.  Taken together, these results suggest that there 
is decreased expression and sensitivity to IGF-1 in skeletal muscle of CKD patients. 
 In addition to simulating protein synthesis, IGF-1 also inhibits skeletal muscle protein 
degradation.  As mentioned previously, activation of the IGF-1 pathway increases 
phosphorylation of Akt and leads to stimulation of protein synthesis.  However, phosphorylated 
Akt also phosphorylates forkhead box O1 (FOXO-1), preventing translocation to the nucleus.  
When IGF-1 signaling is reduced (e.g. in hemodialysis patients) FOXO-1 is primarily 
dephosphorylated and can translocate to the nucleus, increasing expression of E3 ligases, muscle 
like ring finger-1 (MURF-1) and atrogin-1.  This signaling cascade ultimately results in skeletal 
muscle protein degradation through the ubiquitin-proteasome pathway (as reviewed by [91]).  
Therefore, it is not surprising that skeletal muscle ubiquitin, MURF-1 and atrogin-1 mRNA are 
increased in animal models of CKD [87, 92].  Likewise, in human CKD patients, increases in 
inflammation [42] and metabolic acidosis [37] have been shown to up-regulate components of 
the ubiquitin-proteasome pathway and increase skeletal muscle protein degradation. 
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Caspases induce skeletal muscle proteolysis through apoptosis of myonuclei and are 
involved in the initial cleavage of actomyosin, resulting in a 14 KD actin fragment [93].  Similar 
to the ubiquitin-proteasome pathway, IGF-1 signaling can inhibit caspase activation.  However, 
CKD patients have reduced IGF-1 signaling and increased caspase-3 activity compared with 
healthy controls [48].  Moreover, skeletal muscle caspase-3 expression and activity increase over 
the course of a hemodialysis session increasing skeletal muscle protein degradation [42, 48] and 
this increase in caspase-3 has been correlated with the rise in inflammation that occurs during 
hemodialysis [42].  Furthermore, increased 14KD actin fragment has been detected in both 
human [48] and animal [87, 92, 93] models of CKD, indicating increased actomyosin cleavage 
by caspase 3. 
 Muscle regenerative capacity is impaired in hemodialysis patients.  In animal models of 
CKD, a reduced number of key proteins in skeletal muscle regeneration (myoblast determination 
protein 1 (MyoD) and myogenein) have been observed [87, 90].  This correlates with a decrease 
in embryonic myosin heavy chain in skeletal muscle of CKD rodents compared with wild-type 
controls [87, 90].  Moreover, skeletal muscle regeneration is blunted in response to injury [90] 
and treadmill running [87] in animal models of CKD.  Although muscle regenerative capacity 
has been shown to be reduced in animal models of CKD, to date, the effects of CKD and/or 
hemodialysis on skeletal muscle regenerative capacity in humans have not been investigated. 
Myostatin is a negative regulator of skeletal muscle growth and proliferation.  Myostatin 
knockout animals and humans exhibit an extreme amount of muscle mass [94, 95].  However, 
increased myostatin expression has been observed in dialysis patients [86] and animal models of 
CKD [85, 88, 96], although not all studies have observed an increased myostatin expression [84].  
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Future studies are needed to determine to what extent myostatin affects skeletal muscle loss in 
hemodialysis patients. 
In summary, CKD has been shown to result in a net negative balance of skeletal muscle 
protein turnover though reduced protein synthesis and increased of protein degradation.  CKD 
patients have a reduced expression and sensitivity to IGF-1.  In addition, inflammation and 
acidosis up-regulate caspase and the ubiquitin-proteasome pathways to increase skeletal muscle 
protein degradation.  Moreover, skeletal muscle from animal models of CKD has an impaired 
regenerative capacity. Together, these dysregulations result in skeletal muscle loss in 
hemodialysis patients.  
 
Physical function, fall risk and quality of life in hemodialysis patients 
Loss of muscle mass is common in hemodialysis patients and results in reduced strength, 
physical function, and quality of life [5, 23, 97, 98].  Indeed, reduced strength [5, 23, 99], slower 
gait speed [99-101] and poorer performance on a sit-to-stand test [23, 99, 101], have been 
observed in HD patients compared with age-matched healthy controls, even in high functioning 
dialysis patients [99].  Moreover, dialysis patients have increased muscle fatigue [102], poorer 
balance [99], and an increased dual-task cost [100] compared with healthy age-matched controls, 
resulting in an increased fall risk.  Indeed, 1.18 falls/patient-years were reported in a cohort of 
over 300 hemodialysis patients (median age 70.9 yrs, approximately 5 percent nursing home 
residents), a rate similar to elderly nursing home patients (average age approximately 80yrs) [6].  
Moreover, hemodialysis patients are less active than age-matched healthy sedentary controls 
[17], particularly on dialysis days [103], which may further decrease physical function and 
increase disability.  As a result, approximately 20 percent of advanced kidney diseases patients 
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are classified as frail [104] and many hemodialysis patients experience a significantly reduced 
quality of life [105]. 
 
Effects of nutritional interventions on muscle loss, physical function, and quality of life in 
hemodialysis patients 
 Several nutritional interventions have been investigated to prevent declines in muscle 
mass, physical function and quality of life in hemodialysis patients.  Most of these interventions 
have included a protein supplement from a high-quality protein source and many provided 
supplementation during the hemodialysis session (as reviewed by [106]).  Acutely, intradialytic 
oral protein supplementation stimulates protein synthesis and results in a net positive balance in 
skeletal muscle and whole body protein turnover [107, 108].  Chronically, many studies have 
found increases in serum albumin, a marker of nutritional status, after oral protein [109-112] or 
essential amino acid [113, 114] supplementation in malnourished hemodialysis patients.  
Moreover, improvements in physical function [113, 114] and quality of life [110, 112, 115] have 
also been observed after oral supplementation in malnourished patients.  However, the effects of 
oral protein supplementation on patients who do not meet the criteria for malnutrition is less 
studied.  Our lab recently performed a 6 month intervention in which non-malnourished 
hemodialysis patients were supplemented with 27g whey or soy protein for 6 months.  We found 
that intradialyitc protein supplementation improved physical function and quality of life in 
patients who do not meet the traditional criteria for malnutrition [116]. 
 Although oral protein supplementation has been shown to increase markers of nutritional 
status and improve physical function and quality of life in hemodialysis patients, to date, 
nutritional supplementation alone has predominately had little effect on skeletal muscle mass.  
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Many intervention studies have not measured skeletal muscle mass and those that did have not 
observed significant increases in lean mass, as measured by mid-arm circumference [113], serum 
creatinine concentration [112] or DXA [116].  To date, an improvement in lean mass has only 
been observed in one nutritional supplementation study.   Hiroshige et al. [117] supplemented 
elderly malnourished hemodialysis patients with either 12 g branched chain amino acids (BCAA) 
or a placebo daily for 6 months in crossover design and observed an increase in lean mass, as 
measured by bioelectrical impedance analysis.  However, these results have not been replicated 
with more precise measurements of body composition and no additional studies supplementing 
BCAA, or their metabolites, have been performed in hemodialysis patients. 
 
Conclusion 
 Skeletal muscle loss is a common co-morbidity in end stage renal disease patients that is 
likely caused by a number factors including: acidosis, inflammation, insulin resistance, anorexia, 
hormone dysregulation, changes in energy expenditure, and changes in skeletal muscle 
molecular signaling.  Declines in skeletal muscle mass have been shown to result in reductions in 
strength, physical function, an increased fall risk, reduced quality of life, and increased mortality.  
Nutritional interventions have successfully improved nutritional status, physical function, and 
quality of life in this population.  However, to date, nutritional interventions to target muscle loss 
in this population have not been successful.  Therefore, future studies are needed to determine 
successful interventions to attenuate skeletal muscle loss in this critically ill patient population.   
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CHAPTER 3 
EFFICACY OF BETA-HYDROXY-BETA-METHYLBUTYRATE (HMB) 
SUPPLEMENTATION IN ELDERLY AND CLINICAL POPULATIONS 
 
Introduction 
 
Muscle loss is common throughout the ageing process and may begin as early as age 30 
[118].  Approximately 30 percent of muscle mass is lost between the 5
th
 and 8
th
 decade of life 
and rates of muscle loss can reach up to 15 percent per decade by age 70 [119, 120]. Moreover, 
low-levels of muscle mass in the elderly have been correlated with reduced physical function 
[121], decreased quality of life [122] and increased mortality [123].  A similar relationship exists 
in many clinical populations such as cancer or Acquired Immune Deficiency Syndrome (AIDS) 
patients where muscle wasting is common.  Indeed, low levels of lean mass in clinical 
populations have been correlated with reduced physical function, decreased quality of life, 
poorer response to treatment and increased mortality [124-127].  Therefore, interventions to 
maintain or potentially increase lean mass in elderly and clinical populations are needed.  
Recently, beta-hydroxy-beta-methylbutyrate (HMB) has been researched for its muscle sparing 
properties in these populations.  The following review summarizes the evidence for use of HMB 
in human elderly and clinical populations. 
 
 
 
 
 
 
______________________________________________________________________________ 
Reprinted from Nutrition, Volume 29, Authors: Fitschen PJ, Wilson GJ, Wilson JM, and Wilund 
KR, Title: Efficacy of beta-hydroxy-beta-methylbutyrate (HMB) supplementation in elderly and 
clinical populations, Pages 29-36, Copyright (2013) with permission from Elsevier. 
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Methods 
 
 Searches were performed using the Pubmed database using terms such as “HMB,” “beta-
hydroxy-beta-methylbuytrate,”  “HMB muscle,” “HMB supplementation,” and “HMB exercise.”  
Results were thoroughly reviewed for primary research studies on HMB supplementation in 
clinical and elderly populations, HMB supplementation in animal models of disease, HMB safety 
and dosage studies, and studies on the potential mechanism of action of HMB.  In addition, 
review articles on HMB supplementation were obtained and the reference sections of all papers 
were thoroughly examined for appropriate papers.  All papers meeting the inclusion criteria are 
discussed below. 
 
 
Metabolism and dosage 
 
 HMB is a metabolite of the ketogenic amino acid, leucine.  A small amount (~0.3-0.4 
g/day) of HMB is produced endogenously through leucine metabolism.  The first step in leucine 
oxidation is transamination to ketoisocaproate (KIC).   The majority (approximately 95%) of 
KIC is metabolized to isovaleryl CoA by the mitochondrial enzyme, branched-chain α-keto-acid 
dehydrogenase (BCKDH), and ultimately enters the citric acid cycle.   However, a small amount 
of KIC (approximately 5%) is converted to HMB by α-ketoisocaproate dioxygenase in the 
cytoplasm and ultimately metabolized into cholesterol [128]. 
 Although HMB can be synthesized endogenously from leucine, approximately 60g of 
leucine would need to be consumed daily to reach the 3g of HMB per day dosage that has been 
used in most previous studies [129].  High leucine protein sources, such as dairy, eggs and meats 
contain roughly 7-10 percent leucine [130].  Therefore, in order to obtain 60g of leucine from the 
diet, one would have to consume at least 600g of protein from a high leucine protein source 
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daily.  Clearly, this level of consumption is not practical; therefore, in order to obtain 3g 
HMB/day, supplementation of HMB is necessary. 
  When supplemental HMB is consumed, HMB peaks in circulation at 1-2 hours and 
reaches baseline levels by 9 hrs post-consumption, suggesting that consumption of HMB in 
multiple dosages throughout the day may be optimal [131].  Additionally, when 1-6 g HMB is 
supplemented, approximately 14-29 percent is excreted in the urine [131, 132].  Therefore, it 
appears that a majority of supplemental HMB remains in the body.     
 Most researchers seem to agree that the optimal dosage of HMB is 3g/day.  This 
recommendation comes from previous research by Nissen et al. [133] which showed that HMB 
supplementation in strength training healthy subjects increased strength in a dose dependent 
manner in, up to 3g HMB daily.  Furthermore, Gallagher et al. [132] showed that 3g HMB daily 
significantly increased total body strength in healthy strength training subjects compared to a 
control group that strength trained, but did not receive HMB; while, consumption of 6g 
HMB/day did not result in any additional increases in total body strength.  As a result of these 
studies, the dosage of 3g HMB/day is the commonly agreed upon daily dosage of supplemented 
HMB. Unfortunately, no dose-response studies have been conducted in clinical or aging 
populations and it is not clear if 3 grams is the ideal under these conditions or if more may be 
required to optimize HMB’s effects.   
 
 
Safety of HMB 
 
With consumption of any dietary supplement, safety is a concern.  Accordingly, the 
safety of HMB supplementation has been widely studied [134-137].  Early studies in animals 
found that consumption of HMB in dosages as high as 100 g/day in pigs weighing 20 kg 
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(approximately 100 times the g HMB/kg bodyweight dose used in most human studies) for 4 
days had no effect on changes in blood cell numbers, organ weights, or histological lesions 
[134].  Likewise in humans, consumption of dosages as high as 6 g HMB/day for 1 month had no 
effect on liver enzymes, kidney function, cholesterol, white blood cells, hemoglobin, or blood 
glucose [135].  Furthermore, two meta-analyses on HMB supplementation have concluded that 
HMB is safe and does not result in any major side effects [136, 137].  In fact, HMB may actually 
decrease blood pressures, total and LDL- cholesterol, especially in hypercholesterolemic 
individuals [136].  Moreover, 2 relatively short term studies in clinical populations did not have 
any major negative side effects [11, 12].  However, there is less research on the long-term effects 
of HMB supplementation in elderly and clinical populations. Recently, Baier et al. [10] 
examined the effects of 2-3g of HMB daily for one year in the elderly and found that HMB 
consumption did not result in any changes in blood or urine markers of hepatic or renal function 
or blood lipids.  Therefore, it appears that up to one year of HMB supplementation is safe; 
however, future studies should investigate the long-term safety of HMB supplementation, 
especially in clinical populations. 
 
 
Efficacy of HMB in healthy populations and athletes 
 
 Previous studies investigating HMB supplementation in athletes and healthy populations 
have shown mixed results.  A meta-analysis of 9 studies found that HMB resulted in significant 
gains in muscle size and strength [138].  However, a more recent meta-analysis of 11 studies by 
Rowlands et al. [139] concluded that 3-9 weeks of HMB supplementation at a dosage of around 
3g/day resulted in only small to trivial increases in muscle strength and only trivial increases in 
muscle size, regardless of training experience.  As pointed out by Wilson et al. [129], the 
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discrepancies in the results of  HMB supplementation studies in healthy populations may be due 
to many factors including clustering of data in these meta-analysis to include many studies from 
similar groups, small sample sizes, poorly designed, non-periodized training protocols, and lack 
of specificity between training and testing conditions.  Moreover, thus far, direct measures of 
changes in muscle size have been poor and generally indirect, which makes it difficult to truly 
quantify HMB’s effects in healthy populations.  Thus, while the effects of HMB supplementation 
in athletes and healthy populations can be debated, it is beyond the scope of this review to do so.  
Interested readers are encouraged to read Wilson et al. [129]. 
 
Efficacy of HMB in the elderly 
 The effects of HMB supplementation in elderly populations have been examined in 
several studies (Table 1).  Hsieh et al. [140] investigated the effects of HMB in elderly subjects 
receiving tube feeding.  Subjects were assigned to either usual care (n=40) or two grams of HMB 
per day (n=39) for 28 days.  All tube feeding protocols remained the same throughout the study.  
After 28 days, HMB supplementation increased weight, BMI, waist, hip, and calf circumference.  
Additionally, HMB supplementation resulted in a decrease in nitrogen excretion, suggesting that 
HMB either decreased protein breakdown and/or increased protein synthesis.  The authors 
concluded that HMB was beneficial to malnourished elderly receiving tube feeding; however, 
this study did not measure body composition to determine if the increases in weight were from 
lean or fat mass.   
The efficacy of HMB supplementation on lean mass and physical function in healthy 
elderly populations has also been investigated.  Vukovich et al. [141] compared the effects of 8 
weeks of HMB supplementation on body composition and strength in 70 yr old men and women.  
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Subjects were assigned to either 3g HMB per day (n=14) or a placebo containing 3g rice flour 
per day (n=17) and all subjects participated in 5 days of supervised exercise per week.  Strength 
training was completed twice weekly and consisted of 2 sets of 10-15 repetitions on 8 exercises 
at 70 percent of 1 repetition maximum.  On the other 3 days of exercise, subjects participated in 
60 minutes of walking and stretching.  At the end of 8 weeks, upper body strength increased by 
nearly 15 percent  and lower body strength was increased approximately 20 percent in both 
groups; however, there was no difference in strength changes between groups.  A near significant 
0.8 kg increase in lean mass (p=0.08) was observed in the HMB group measured by skin fold 
calipers, while no change was observed in the placebo group.  On a subset of subjects, lean body 
mass was also assessed via DXA; however, no difference was observed between groups.  The 
HMB group also had an approximately 8 percent decrease in fat mass, measured via CT scan; 
however, no differences in lean mass change were observed between groups, as measured by CT.  
Overall, HMB decreased fat mass and may have increased lean mass over a relatively short term 
in exercising adults; however, this increase in lean mass did not appear to result in additional 
increases in muscle strength.  Moreover, measurements of basic physical function and quality of 
life were not performed so it cannot be determined if the additional lean mass gained as a result 
of HMB supplementation resulted in significantly improvements clinically significant outcomes 
over strength training alone.  Additionally, measurement of lean mass with skin fold calipers is 
not the gold standard method for measuring body composition and skin fold caliper 
measurements did not show the same results as the subset of subjects who received DXA scans.  
Although the results in this study provide mild support for the use of HMB in exercising elderly 
individuals, future studies investigating the effects HMB supplementation in strength training 
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elderly employing a longer duration intervention and using more precise measurements of body 
composition are needed to confirm these findings. 
 The effects of HMB supplementation in the elderly without an exercise intervention have 
also been examined.  Flakoll et al. [142] investigated the effects of 12 weeks of HMB 
supplementation in subjects over 62 years living in nursing homes.  Subjects were randomly 
assigned to either 2g HMB, 5g arginine, and 1.5g lysine daily (n=27) or a placebo (n=23).  A 
near significant 0.7 kg increase in lean mass was observed (p=0.08), as measured by bioelectrical 
impedance and Bod Pod, while no changes in lean mass were observed in the placebo.  
Moreover, subjects in the HMB group significantly decreased “timed up and go” test time by 2.3 
sec, increased leg extensor force by 3.0 kg, and increased handgrip strength compared to the 
placebo.  These improvements in physical function suggest that HMB supplementation can 
improve clinically significant outcomes in the elderly.  Moreover, all changes were observed 
without an exercise intervention suggesting that HMB alone may be able increase lean mass and 
improve physical function in the elderly.   
 To further investigate the ability of HMB to increase lean mass and physical function, 
independently of exercise, Baier et al. [10] investigated the effects of 1 year of HMB 
supplementation in elderly subjects age 65 or older.  Subjects were given either 2-3g HMB/5-
7.5g arginine/1.5-2.25g lysine (n=40) or an isonitrogenous control made up of non-essential 
amino acids (n=37), daily.  One year of HMB supplementation increased lean mass by 0.88 kg as 
measured by BIA and 0.55 kg as measured by DXA while no significant changes in lean mass 
ever observed in the control group.  However, HMB did not result in any differences in bone 
density, “timed up and go” test time, chair stand, handgrip strength, leg strength, or quality of 
life between groups.  Overall, this study indicates that 1 year of HMB supplementation in 
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sedentary older adults could increase lean mass.  Additionally, HMB supplementation did not 
improve physical function, which differed from the previous study by Flakoll et al. [142].   
Interestingly, additional analysis of the Baier  [10] study by Fuller et al. [143] found that 
vitamin D status affected strength gains.  Subjects with adequate vitamin D status experienced a 
nearly 21 percent net gain in total body strength during the 1 year HMB intervention, while those 
who did not have adequate vitamin D status did not gain strength after HMB supplementation.  
This suggests that vitamin D deficiency may blunt the increase in strength gains observed with 
HMB supplementation.  
 A possible confounder in many previous HMB supplementation studies in elderly 
populations was that lysine and arginine were supplemented along with HMB so it is not 
possible to determine which of the supplements were effective or if there was a possible 
synergistic effect.  To isolate HMB’s effects from lysine or arginine our lab recently utilized a 
fisher 344 rat model (unpublished data) to investigate the effects of HMB supplementation from 
young to middle (44 to 60 wks) age and from old to very old age (86 to 102 wks) [144].  HMB 
was given as 1 percent of the diet.  The supplementation period of 16 weeks represented 
approximately 16 % of the rats’ lifespan.  We found that body fat mass increased by nearly 50 
percent from young to middle age, measured by DXA (p<0.05), but that HMB supplementation 
prevented this gain.  This is important as research indicates that the onset of fat gain may 
increase whole body inflammation and initiate sarcopenia.  We also found that supplementation 
with HMB throughout old age prevented any significant loss in muscle fiber dimensions and 
blunted the rise in the ubiquitin pathway typically seen with age in the rats’ soleus muscles.  
Finally, HMB decreased fat mass and improved normalized limb strength by 23 percent as 
measured by the grip strength test [145] in the old group.  Thus, it is possible that HMB alone 
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supplemented throughout old age can improve strength, maintain muscle size, and create an 
overall leaner phenotype.    
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Table 1. Summary of beta-hydroxy-beta-methybutyrate (HMB) supplementation studies in 
elderly humans. 
 
Study Dosage 
(Daily) 
Length 
of Study 
Exercise Results and Comments 
        
Vukovich 2001 
[141] 
3g HMB 
 
8 weeks 2 days strength 
training and 3 
days aerobic 
exercise 
HMB (n=14) ↑ LBMa by 0.8 kg 
measured by calipers (p=0.08) 
No difference in LBM measured by 
DXA
b 
or  strength between HMB and 
placebo group (n=17) 
 
Flakoll 2004 [142] 2g HMB 
5g Arginine 
1.5g Lysine 
12 weeks None HMB (n=27) ↑ LBM by 0.7 kg measured 
by  BIA
c
 (p=0.08) 
HMB ↑ leg extensor strength by 3 kg, ↑ 
grip strength, and ↓ “timed up and go” 
test time by 2.3 sec 
No changes in LBM, leg strength, grip 
strength, or “timed up and go” test time 
in placebo (n=23) group 
 
Baier 2009 [10] 2-3g HMB 
5-7.5g Arginine 
1.5-2.25g Lysine 
1 year None HMB (n=40) ↑ LBM by 0.55kg 
measured by DXA  
No change in LBM in control group 
(n=37)
 
No change in bone mineral density, 
strength, physical function, or quality of 
life in either group 
 
Hsieh 2010 [140] 2g HMB 4 weeks None Subjects receiving tube feeding 
HMB (n=39) ↑ bodyweight, BMId, hip, 
and calf circumference 
HMB ↓ nitrogen excretion 
No changes in BMI, hip, or calf 
circumference in control group (n=40) 
 
Fuller 2011[143] 2-3g HMB 
5-7.5g Arginine 
1.5-2.25g Lysine 
 
1 year None Additional analysis of  Baier [10]  
Vitamin D Status affected strength gains 
HMB + adequate vitamin D status ↑ total 
body strength by 21 percent 
No change in strength in HMB 
supplemented subjects with vitamin D 
deficiency or in placebo group 
a
LBM = lean body mass, 
b
DXA = dual x-ray absorptiometry, 
c
BIA = bioelectrical impedance, 
d
BMI = body mass index 
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Efficacy of HMB in clinical populations 
 Patients with chronic disease such as cancer and AIDS experience significant muscle 
loss, which leads to decreased physical function, quality of life and survival [127].  Numerous 
nutritional interventions have been investigated in an attempt to counteract muscle wasting in 
these populations; however, many of these interventions have been unsuccessful in attenuating 
muscle loss (reviewed in Klein et al. [146]).  Recently, HMB has been investigated for its anti-
catabolic effects in clinical populations such as cancer, AIDS, and chronic obstructive pulmonary 
disease (COPD) (Table 2).  
Several studies support the efficacy of HMB to attenuate muscle loss in cancer cachexia.  
Numerous animal models of cancer have shown benefits from HMB supplementation including 
attenuation of weight loss [147-149] and tumor growth [148], and prolonged survival time [150].  
The reduction in tumor growth was thought to occur through a reduction in nuclear factor-κB 
p65 subunit expression (34).  Likewise, the efficacy of HMB supplementation in human cancer 
patients has been previously demonstrated.  For instance, May et al. [11] recruited cancer 
patients with solid tumors that had a documented weight loss of greater than 5% and a prognosis 
of greater than 3-month survival.  Patients were assigned to either 3g of HMB, 14g arginine, and 
14g glutamine (n=18) or an isonitrogenous mixture of nonessential amino acids (n=14) daily.  
HMB supplementation resulted in an approximately 1 kg increase of lean mass in 4 weeks, as 
determined by Bod Pod analysis.  Despite these promising results, to our knowledge no 
additional human trials have been conducted in cancer patients.  Future studies should investigate 
the long-term effects of HMB supplementation in cancer patients to determine if the gains in lean 
mass observed in the first 4 weeks are maintained long term and to determine if HMB can 
increase survival time in humans, as was shown in rats. 
27 
 
 The efficacy of HMB supplementation to attenuate muscle wasting in AIDS has also 
been investigated.  Clark et al. [12] recruited AIDS patients with a weight loss of greater than 5%  
over the previous 3 months.  Subjects were assigned to either 3g of HMB, 14g arginine, and 14g 
glutamine (n=22) or an isocaloric maltodextrin control (n=21) daily.  Similar to the results 
observed in cancer patients, 8 weeks of HMB supplementation in AIDS patients increased lean 
mass by 2.6 kg in 8 weeks, as determined by Bod Pod.  Moreover, HMB supplementation 
increased CD3+, CD4+, and CD8+ cell numbers indicating that HMB may improve the immune 
system of immunocompromised AIDS patients.  Despite these findings, no additional clinical 
trials have been performed in AIDS patients.  Therefore, similar to HMB research in cancer 
patients, future studies should investigate the long-term effects of HMB supplementation in 
AIDS patients and also look into possible immune system benefits in AIDS patients as a result of 
HMB. 
 The effects of HMB supplementation in trauma patients have also been investigated.  
Kuhls et al. [151] recruited trauma patients that were candidates for enteral feeding.  Subjects 
received a daily dose of either 3g of HMB, 14g arginine, and 14g glutamine per day (n=22), 3g 
HMB alone per day (n=28), or an isonitrogenous control (n=22).  After 4 weeks, both groups 
receiving HMB supplementation reduced nitrogen excretion.  The reduction in protein 
breakdown may have been observed as a result of a decrease in protein breakdown, increase in 
protein synthesis, or a combination of both events occurring simultaneously.  However, no 
significant differences were observed in inflammatory markers such as interleukin-6 (IL-6) and 
C-reactive protein (CRP), or pre-albumin, a marker of nutritional status.  This indicates that 
HMB may reduce muscle protein breakdown in trauma patients; however, this does not appear to 
happen through a decrease in inflammation.  Although these results support the use of HMB in 
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trauma patients, the efficacy of HMB supplementation to maintain lean mass has not been 
investigated in this population.  
 Although the previous study did not find a change in inflammation in trauma patients, 
there is some evidence that HMB may be anti-inflammatory in certain clinical populations.  
Hsieh et al. [152] assigned COPD patients to either 3g HMB (n=18) or a placebo (n=16) daily 
for 7 days and found that HMB supplementation reduced CRP from 111.56 ± 91.47 to 46.19 ± 
45.29 mg/L while no change in CRP was observed in the placebo group.  In addition, HMB 
supplementation reduced white blood cell numbers.  However, HMB supplementation also 
increased total cholesterol, an effect that is different than previous studies, which have primarily 
shown a decrease in total cholesterol [136].  Although HMB may decrease inflammation in 
COPD patients, the mechanism by which this happens is not well understood.  Moreover, the 
effects of HMB supplementation on lean mass and strength have not been investigated in COPD 
patients. 
All of the previously discussed studies supported the use of HMB in clinical populations; 
however, not all studies have found beneficial effects of HMB supplementation in clinical 
populations.  Marcora et al. [153] supplemented Rheumatoid arthritis patients with either 3g 
HMB, 14g arginine, and 14 g glutamine per day (n=18) or an isonitrogenous mixture of 
nonessential amino acids (n=18) for 12 weeks.  HMB supplementation did not result in any 
change in total body mass, lean mass, fat mass, bone mineral density, or strength.  Moreover, 
Clements et al. [154] supplemented the same HMB, arginine, and glutamine cocktail (n=14) or 
provided usual care (n=16) to gastric bypass patients after surgery for 8 weeks and also found 
that HMB supplementation had no effect on body weight, BMI, fat mass, lean mass, or resting 
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metabolic rate.  Discrepancies in the results of these studies should be investigated to determine 
the potential reasons for differences in HMB efficacy between clinical populations.   
A possible confounding factor in the previously discussed studies was that nearly all 
studies supplemented a cocktail of HMB along with arginine and glutamine, which were added 
to the cocktail for their effects on muscle protein synthesis, immune function, and wound healing 
[155, 156].  Therefore, it is not possible to determine if the effects observed were due to HMB 
supplementation alone, the addition of the amino acids, or a possible synergistic effect of HMB, 
arginine, and glutamine.  Therefore future studies are advised to investigate this relationship and 
to determine the effects of HMB alone in human clinical populations.  
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Table 2. Summary of beta-hydroxy-beta-methybutyrate (HMB) supplementation studies in 
clinical populations. 
 
Study Population Dosage Study 
Length 
                       Results 
Clark 2000 [12] AIDS 
  
3g HMB 
14g Glutamine 
14g Arginine 
8 weeks HMB (n=22) ↑ LBMa by 2.6 kg measured by 
Bod Pod 
Placebo group (n=21) ↓ LBM by 0.7 kg 
measured by Bod Pod 
HMB ↑ CD3+, CD4+, and CD8+ cell numbers 
 
May 2002 [11] Cancer 3g HMB 
14g Glutamine 
14g Arginine 
24 weeks HMB (n=18) ↑ LBM by approximately 1 kg 
measured by Bod Pod 
Placebo group (n=14) had no change in LBM 
 
Marcora 2005 
[153] 
Rheumatoid 
Arthritis 
3g HMB 
14g Glutamine 
14g Arginine 
12 weeks No effects on LBM, fat mass, bone mineral 
density, or strength in either HMB or placebo 
group (n=18 in each group) 
 
Hsieh 2006 
[152] 
Chronic 
Obstructive 
Pulmonary 
Disease 
 
 
3g HMB 1 week HMB (n=18) ↓ CRPb and WBCc count 
No change in CRP in control group (n=16) 
Kuhls 2007 
[151] 
Trauma 
Patients 
3g HMB 
14g Glutamine 
14g Arginine 
 
4 weeks HMB (n=28) and HMB/Arginine/Glutamine 
(n=22)  groups but not placebo (n=22), ↓ 
nitrogen excretion 
No change in CRP, IL-6
d
, or pre-albumin in 
any group 
 
Clements 2011 
[154] 
Gastric 
Bypass 
3g HMB 
14g Glutamine 
14g Arginine 
8 weeks No differences total bodyweight, BMI
e
, fat 
mass, LBM, or resting metabolic rate between 
HMB (n=14) and placebo (n=16) groups 
a
LBM = lean body mass, 
b
CRP = C reactive protein, 
c
WBC = white blood cell, 
d
IL-6 = 
interleukin-6, 
e
BMI = body mass index 
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Efficacy of HMB in animal models of disease 
The previously discussed studies are the only published investigations on the efficacy of 
HMB supplementation in human clinical populations.  However, HMB supplementation has also 
been investigated in animal models of muscular unloading, sepsis and muscular dystrophy.  Hao 
et al. [157] investigated the effects of HMB using an animal model of unloading and reloading.  
They found that rats supplemented with HMB had significantly greater force production and 
increased plantaris and soleus cross sectional area after reloading.  Moreover, HMB reduced the 
number of apoptotic nuclei after unloading.  Kovarik et al. [158] induced mice with sepsis and 
injected either HMB or saline.  HMB reduced protein degradation, leucine oxidation, and 
proteosome activity indicating that HMB may attenuate muscle loss during sepsis.  Additionally, 
Payne et al. [159] gave a combination therapy of HMB, creatine monohydrate, conjugated 
linolenic acid and alpha linoleic acid to MDX mice (an animal model of muscular dystrophy) 
and found that the cocktail increased grip strength, decreased grip strength fatigue, and decreased 
the amount of internalized myonuclei.  These results indicate that HMB may be able to decrease 
muscle damage in muscular dystrophy and result in an increase in physical function.  However, 
to date no human studies of HMB supplementation in models of injury rehabilitation and 
unloading, muscular dystrophy or sepsis have been performed.   
While HMB supplementation has shown positive results in clinical populations, more 
work is needed to determine the long-term efficacy and safety of HMB in the clinical 
populations discussed. Furthermore, research on the efficacy of HMB supplementation should be 
extended to additional clinical populations, such as congestive heart failure, diabetes mellitus, 
chronic kidney disease, neurodegenerative diseases, or patients recovering from injuries.  
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HMB mechanism of action 
Muscle tissue mass represents the net balance between muscle protein synthesis and 
degradation. The continuous process of building and replacing muscle protein allows muscle to 
repair and adapt to environmental conditions. Net protein balance is positive during growth when 
protein synthesis exceeds degradation, while net balance is negative during weight loss, aging, 
and in clinical populations when degradation exceeds synthesis. Accordingly, numerous studies 
have investigated the effects on HMB on muscle protein balance.  A summary of the potential 
mechanisms by which this occurs is found in Figure 2.  Results of studies using cultured muscle 
cells have found that HMB reduces muscle protein degradation [147, 160].  Moreover, HMB has 
been shown to decrease whole body proteolysis in vivo [161].  However, the effects of HMB on 
muscle protein synthesis have shown mixed results with studies finding that HMB 
supplementation results in increases [147] or no change [162] in muscle protein synthesis.  
Despite the discrepancies in the results of turnover studies, HMB supplementation has been 
shown to result in increases in phosphorylation of the mammalian target of rapamycin (mTOR) 
and its downstream signaling targets, indicating an increase in skeletal muscle protein translation 
[149, 160].  Additionally, increased muscle insulin like growth factor (IGF-1) expression has 
been observed after culture of myoblasts with HMB, which may contribute to an increase in 
protein synthesis [163].  Overall, it appears that HMB inhibits protein degradation and may also 
stimulate protein synthesis which may be due at least in part to an upregulation of muscle IGF-1, 
and increased mTOR activation. 
 HMB may attenuate protein degradation through inhibition of multiple catabolic 
pathways.  The ubiquitin-proteosome pathway is upregulated in catabolic states [164], and 
results in increased degradation of proteins.  However, HMB has been shown to decrease 
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ubiquitin-proteosome expression [147] and activity [147, 158, 161, 165] during catabolic states, 
thereby attenuating ubiquitin-proteosome induced protein degradation.   
 Caspases are commonly upregulated in catabolic states and induce muscle proteolysis by 
apoptosis of myonuclei, and are also involved in the initial cleavage of the actomyosin complex 
[166].  However, HMB has been shown to attenuate increases in activated caspases in catabolic 
states such as skeletal muscle unloading [157] and in skeletal muscle cells cultured with large 
concentrations of TNF alpha and angiotensin II [167].  In these studies, the decrease in caspase 
activation was correlated with decreased myonuclear apoptosis [157, 167].  Thus, it appears that 
HMB attenuates apoptosis in catabolic states through attenuation of caspase activation. 
 Muscle regenerative capacity is impaired in the elderly and cachexic states, which may 
further contribute to muscle protein catabolism [168].  Recently, HMB has been investigated for 
its effects on muscle regenerative capacity.  Kornasio et al. [163] cultured myoblasts in a serum 
starved state to induce apoptosis.  When myoblasts were incubated with HMB, expression of 
Myo D and myogenin were increased, which suggests that HMB may increase satellite cell 
activation and increase muscle regenerative capacity.  This may have occurred though an 
observed increased in Akt phosphorylation which may have decreased FOX-O translocation and 
resulted in a reduction in atrogin-1, which may have resulted in reduced degradation of Myo D 
[144].  Moreover research from our lab indicated that old resistance trained rats supplemented 
with HMB were able to increase IGF-1 mRNA expression, while those not provided HMB did 
not (unpublished data).  Additionally, HMB decreased apoptosis of myoblasts, which suggests 
that HMB may be able to attenuate the reductions in satellite cell numbers observed in the 
elderly and cachexic states [169, 170]. 
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 Increased inflammation is common in ageing and chronic disease and may lead to an 
increase in muscle protein degradation through the upregulation of the ubiquitin proteasome 
pathway [171].  As mentioned previously, HMB may be able to decrease systemic inflammation 
in clinical populations [152]; however, not all studies have found reductions in inflammatory 
markers in human clinical populations following HMB supplementation [151].  Recently, Nunes 
et al. [172] investigated the mechanism by which HMB affects inflammation by culturing human 
peripheral blood mononuclear cells (PBMCs) from healthy subjects in the presence of 
concanavalin A (ConA)to stimulate an inflammatory response, and increasing concentrations of 
HMB.  PBMCs cultured with HMB and ConA had significantly reduced production of 
inflammatory cytokines including tumor necrosis factor alpha and interferon gamma compared 
with PBMCs cultured with ConA alone.  These results suggest that the decrease in muscle 
protein catabolism by HMB may be due in part to the effect of HMB on inflammatory cells; 
however, future studies are needed to confirm this potential mechanism. 
 Overall, HMB appears to exert its effects on skeletal muscle protein metabolism through 
numerous mechanisms, including improved muscle protein balance.  HMB may increase skeletal 
muscle protein synthesis through activation of the mTOR pathway and by increasing skeletal 
muscle IGF-1 expression.  In addition, HMB may decrease protein degradation by decreasing 
activity and expression of the ubiquitin-proteosome pathway and caspases.  Moreover, HMB 
may reduce inflammation and have beneficial effects on muscle regeneration.  However, it 
should be noted that many of the mechanistic studies were performed in animal or cell culture 
models where dosages of HMB were much larger than the dosages commonly used in human 
studies.  Thus, future studies are needed to investigate the mechanisms of HMB action using 
more physiological doses. 
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Figure 1. Potential Mechanisms by which HMB increases anabolic and decreases catabolic 
pathways in skeletal muscle.  Italicized text refers to signaling pathways that are decreased in the 
skeletal muscle cells of elderly and clinical populations as compared to healthy populations, 
while bold text refers to signaling pathways that are increased.  HMB may increase protein 
synthesis by decreasing inflammation, increasing IGF-1, and increasing protein translation 
through activation of mTOR.  Additionally, HMB may decrease protein catabolism through 
down regulation of the ubiquitin proteasome pathway and reductions in caspase activity.  
Abbreviations: HMB – beta-hydroxy-beta-methylbutyrate; IGF-1 – insulin like growth factor-1; 
IRS-1 – insulin receptor substrate-1; mTOR – mammalian target of rapamycin; UB – ubiquitin; 
ROS – reactive oxygen species; TNF-α – tumor necrosis factor alpha. 
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Conclusions 
 Muscle loss is common during aging and in chronic diseases, leading to reduced physical 
function, a decreased quality of life, and increased mortality.  Recently, HMB has been shown to 
attenuate muscle loss in the elderly and in clinical populations such as AIDS and cancer patients; 
however, a limited number of studies have investigated this question, with relatively small 
sample sizes.  In addition, the effects of HMB in clinical populations appear to differ depending 
on the population investigated.  Accordingly, future studies should investigate the effects of 
HMB in other catabolic clinical populations.  Overall, several studies support the efficacy of 
HMB supplementation in the elderly and clinical populations as a means to increase lean mass 
and strength; however, the data is not entirely consistent.  Larger, long-term studies are needed to 
clarify these promising preliminary results.    
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CHAPTER 4 
PLASMA BETA-HYDROXY-BETA-METHYLBUTYRATE (HMB) CLEARANCE IN 
HEMODIALYSIS PATEINTS: A PILOT STUDY 
 
Introduction 
Beta-hydroxy-beta-menthybutyrate (HMB) is a metabolite of the amino acid leucine that 
has been shown to attenuate muscle mass loss in elderly and clinical populations [13].  In adults 
with normal renal function, approximately 20-25 percent of supplemental HMB is cleared by the 
kidney while the majority is cleared through conversion to either Acetyl CoA or cholesterol 
[131].  However, the clearance of HMB in individuals with impaired renal function is unknown.   
Recently, Sipahi et al. [173] performed a retrospective analysis investigating the effects 
of 4 weeks of HMB, arginine, and glutamine supplementation on foot ulcer healing in diabetic 
maintenance hemodialysis (MHD) patients and observed a beneficial effect of supplementation.  
Additionally, no adverse effects of HMB supplementation were observed suggesting that HMB 
supplementation in this population is safe.  However, to date, no other studies have been 
performed investigating HMB supplementation in MHD patients and the time course of 
supplemental HMB clearance in patients with impaired renal function is unknown.  Therefore, 
the purpose of this small pilot study was to determine the clearance of plasma HMB in 
hemodialysis patients during dialysis and after supplementation.   
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Methods 
Participant characteristics 
 MHD patients (n=8) receiving thrice weekly hemodialysis treatment for at least 3 months 
were recruited from dialysis clinics in Champaign, IL.  Patients were excluded if they were not 
between 30-80 years of age, weighed greater than 350lbs or if they were currently taking an 
HMB supplement or HMB containing product.  All patients were informed of the risks and 
benefits of the study protocol and provided written consent prior to participation.  In addition, all 
patients received physician approval prior to participation. 
 
Intervention protocol 
On day 1, blood (5ml) was obtained at the beginning and 3hrs after the start of a 
hemodialysis treatment to determine the effects of hemodialysis on basal HMB concentrations.  
One week later, Calcium-HMB (3g) was given to MHD patients at the start of a hemodialysis 
treatment.  Blood samples were obtained at 0, 1, 2, 3, and 48hrs after the start of the 
hemodialysis treatment. An additional blood sample was obtained 7 days after calcium-HMB 
consumption.  Plasma HMB in all samples was analyzed by Metabolic Technologies Inc. (Ames, 
IA) using the methods described in [174].   
 
Statistical analysis  
Statistical analyses were performed using SPSS Version 22 (IBM, Armonk, NY).  All 
data are presented as mean ± standard deviation, unless otherwise indicated.  Changes in basal 
plasma HMB concentration were analyzed by paired t-test.  Changes in plasma HMB 
concentration after HMB supplementation were analyzed using a repeated measure ANOVA.  
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When ANOVA indicated a main effect, protected LSD was used for pair-wise comparisons.  For 
all statistical tests, significance was determined with a 5 percent chance of type 1 error.   
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Results 
Participant characteristics are displayed in Table 1.  On day 1, after 3 hours of 
hemodialysis treatment, basal plasma HMB levels were significantly reduced (p<0.001, Figure 
1).  After consumption of 3g supplemental calcium-HMB, plasma HMB was elevated within 1hr 
(p=0.006), peaked at 3hrs, remained significantly elevated for 48hrs (p=0.037), and returned to 
baseline by 7 days (Table 2).   
 
 
 
Table 1. Participant Characteristics 
 
Variable  Value 
Number 8 
Gender (Male/Female) 2 / 6 
Age 53 (12) 
Diabetes (Yes/No) 6 / 2 
Smoking (Yes/No) 2 / 6 
BMI 30.4 (7.4) 
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Figure 1. Plasma HMB clearance during a standard hemodialysis treatment.  * indicates 
significant difference from time 0 hrs. 
 
 
 
Table 2. Plasma HMB clearance following consumption of a 3g HMB supplement at the start of 
hemodialysis treatment. 
Time 
Plasma HMB Concentration  
(nmol/ml) 
0 hr 3.8 (0.8) 
1 hr 146.9 (55.2)* 
2 hr 201.1 (37.8)* 
3 hr 257.8 (39.8)* 
48 hr 12.1 (2.2)* 
7 days 4.4 (0.7) 
* Significantly different than 0hr 
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Discussion 
The primary findings from this acute pilot study were that plasma HMB concentration 
decreased during a standard hemodialysis session.  Additionally, supplemental HMB is cleared 
in patients with impaired kidney function.  These preliminary findings in conjunction with a 
previous 4 week HMB supplementation intervention in MHD patients [14] suggest that 
supplemental HMB at a dosage of 3g/day is not harmful in this patient population. 
Hemodialysis treatment results in an increase in skeletal muscle protein catabolism 
contributing to reductions in lean mass up to 1-3kg annually in incident hemodialysis patients 
[2].  Therefore, interventions to attenuate muscle catabolism during hemodialysis treatment are 
needed.  HMB has been shown to attenuate skeletal muscle protein catabolism through a number 
of mechanisms (as reviewed by [13]); however, in the present study we observed a reduction in 
plasma HMB concentration by approximately 50 percent during a standard hemodialysis session.  
This high rate of clearance is likely due to the similarity in size between HMB and amino acids, 
which are removed through the dialysis membrane at a rate of 6-8g per dialysis session [82].  It 
is also possible that the reduction in plasma HMB levels during hemodialysis may further 
contribute to increased rates of skeletal muscle protein catabolism at this time due to the anti-
catabolic properties of HMB.  
In adults with normal renal function, approximately 20-25 percent of supplemental HMB 
is cleared by the kidney and the remainder is converted to acetyl CoA and/or cholesterol.  
However, the rate at which supplemental HMB is cleared in patients with impaired renal 
function was previously unknown.  In the present study, supplementation of 3g HMB at the start 
of hemodialysis treatment resulted in a peak in plasma HMB at approximately 3hrs after 
supplementation, significantly longer than previously reported in healthy adults [131].  This 
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discrepancy may have been due to a reduction in splanchnic perfusion during hemodialysis 
[175].  Additionally, participants in the previous study were fasted while we did not control for 
food intake in the present study due to the high prevalence of diabetes in our patient population. 
Plasma HMB concentration was nearly reduced to baseline levels after 48hrs.  
Importantly, the majority of this clearance occurred during the interdialytic period and 
independently of kidney function and/or hemodialysis suggesting that plasma HMB was likely 
cleared though conversion to cholesterol to either Acetyl CoA or cholesterol [131].  Moreover, at 
7 days, plasma HMB returned to baseline levels in all patients.  Importantly, these results suggest 
that supplementation of HMB at the start of hemodialysis, a period in which HMB is rapidly 
cleared, results in a significant and sustained elevation in plasma HMB levels. 
The present pilot study has a number of limitations.  We did not control nutritional intake 
prior to our intervention due to the number of diabetics in our patient population.  We also did 
not measure dialysate HMB concentrations so it is unclear what percentage of supplemental 
HMB is cleared through the dialysis membrane.  We only measured plasma HMB at a limited 
number of time points so we are only able to provide a rough time course of HMB clearance 
kinetics in patients with impaired renal function.  In addition, we included a small sample size.  
Despite this, we were able to observe statistically significant changes in plasma HMB 
concentrations.  Based on the findings of this study and previous work [14] we conclude that 
supplemental HMB results in meaningful increases and clearance of plasma HMB in MHD 
patients.  Furthermore, HMB supplementation does not appear to adversely affect patients with 
impaired renal function based upon these preliminary findings. 
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CHAPTER 5 
EFFECTS OF BETA-HYDROXY-BETA-METHYLBUTYRATE (HMB) 
SUPPLEMENTATION ON LEAN MASS, STRENGTH, AND PHYSICAL FUNCTION 
IN MAINTENANCE HEMODIALYSIS PATIENTS 
 
Abstract 
Patients with renal failure undergoing maintenance hemodialysis (MHD) therapy suffer 
from a number of co-morbidities including skeletal muscle loss, reduced physical function, a 
significantly increased fall risk, and reduced quality of life (QOL).  Therefore, interventions to 
combat these co-morbidities are needed.  Beta-hydroxy-beta-methylbutyrate (HMB) is a 
metabolite of the amino acid leucine that has been shown to improve lean mass and physical 
function in the elderly and clinical populations, but had not previously been studied in MHD 
patients.  We performed a double blind, placebo controlled, randomized trial to assess the effects 
of daily HMB supplementation on co-morbidities in MHD patients.  MHD patients were 
recruited and assigned to either daily supplementation with HMB (n=16) or placebo (n=17) for 6 
months.  No significant effects of HMB on lean mass, strength, physical function, fall risk, or 
quality of life were found using an intent-to-treat analysis.  However, upon analysis of plasma 
HMB concentrations, 5 of 16 patients (31%) who completed the study in the HMB group were 
found to be non-compliant at 3 or 6 months.  Therefore, we performed a per-protocol analysis 
with compliant participants only.  Although this analysis was underpowered, we observed a trend 
for improvements in several physical function tests with HMB supplementation.  However, no 
effects of HMB were observed for lean mass, strength, fall risk, or quality of life.  As a whole, 
these results do not support the efficacy of HMB to attenuate muscle loss and declines in 
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physical function in MHD patients.  However, the observed low-compliance with study pills may 
have affected the results.  Moreover, it highlights the need for future interventions targeted at 
reducing pill burden and improving pill compliance in this population. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
46 
 
Introduction 
Patients with renal failure undergoing maintenance hemodialysis (MHD) therapy 
experience a number of co-morbidities, including skeletal muscle loss, which occurs for several 
reasons including: metabolic acidosis, inflammation, insulin resistance, decreased nutrient 
intake, hormonal abnormalities, an elevated metabolic rate, and loss of amino acids into the 
dialysate (as reviewed by [30, 31]).  Moreover, the dialysis process has been shown to up-
regulate expression of genes involved in skeletal muscle protein degradation and result in a 
breakdown of skeletal muscle proteins [32].  In addition, this decline in skeletal muscle mass 
contributes to reductions in physical function [5], a significantly increased fall risk [6], and 
reduced quality of life (QOL) [7].  Pharmacological agents have been investigated to treat 
muscle loss in MHD patients; however, many of these treatments are expensive and have 
undesirable side effects [8, 9].  As a result, low-cost interventions designed to attenuate declines 
in muscle mass are needed in this population.   
Beta-hydroxy beta-methylbutyrate (HMB) represents a potential low-cost nutritional 
intervention to attenuate muscle loss in MHD patients.  HMB is a metabolite of the amino acid 
leucine that has been shown to safely attenuate muscle mass loss in other clinical populations 
with accelerated muscle loss, such as the elderly [10], cancer [11], and AIDS  patients [12], 
primarily through reductions in skeletal muscle protein catabolism (as reviewed by [13]).  A 
recent study examining the effects of 4 weeks of HMB supplementation in diabetic MHD 
patients observed beneficial effects on wound healing [14]; however, lean mass, strength, 
physical function, and quality of life were not measured.  Therefore, the primary purpose of this 
trial was to determine if oral supplementation with HMB attenuates muscle loss and declines in 
muscle strength and physical function in MHD patients. 
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Methods 
Study overview  
MHD patients (n=41) were recruited from dialysis clinics in Champaign, IL and Chicago, 
IL and randomly assigned to daily supplementation with HMB (n=20) or placebo (n=21) for 6 
months.  Patients in the HMB group ingested three 1000mg capsules of Calcium-HMB 
(Optimum Nutrition, Aurora, IL) 7 days a week for 6 months.  Patients in the CON group 
ingested a non-nutritive placebo capsule daily.  At baseline and 6 months following the start of 
the supplementation period, patients came to the lab for measurement of clinical outcomes. 
 
Study participants 
Patients who had been receiving at least twice weekly hemodialysis for greater than 3 
months were recruited.  Patients were excluded if they were not between 30-80 years of age, 
weighed greater than 350lbs due to weight restrictions of the DXA machine, were not willing to 
be randomized to HMB or placebo, or if they were currently taking an HMB supplement or 
HMB containing product.  All patients were informed of the risks and benefits of the study 
protocol and provided written consent prior to participation.  In addition, all patients received 
written physical approval prior to participation. 
 
Randomization and intervention protocol 
Following baseline testing, patients were randomly assigned to either the HMB or 
placebo group.  Patients in the HMB group ingested three 1000mg capsules of Calcium-HMB 
(Metabolic Technologies Inc, Ames, IA) 7 days a week for 6 months.  These pills do not contain 
significant amounts of nitrogen, potassium, or phosphorous.  We chose a dose of 3g HMB/day 
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because previous research has shown that 3g/day HMB significantly increased lean mass in other 
clinical populations such as the elderly [10], cancer [11], and AIDS [12] patients.  Patients in the 
placebo group consumed non-nutritive pills containing cellulose, caramel, beet root, magnesium 
stearate, and silicon.  These placebo pills have been used in a previously published study in our 
laboratory [176].  Patients in both groups received a pill bottle containing a month’s supply of 
capsules (HMB or placebo) prior to the beginning of each month. 
 
Compliance  
Blood was obtained at baseline, 3, and 6 months for plasma HMB analysis (as described 
by [174]) to assess compliance.  All plasma HMB analysis was performed by Metabolic 
Technologies Inc. (Ames, IA) by blinded assessors.  All patients who completed the study were 
included in intent-to-treat analysis; however, patients with an absence of elevated plasma HMB 
levels at 3 and 6 months in the HMB group (defined as at least a 3-fold increase in plasma HMB 
from baseline), were excluded from per-protocol analysis. 
 
Outcome testing 
At baseline and after 6 months of intervention, patients came to the lab for measurement 
of clinical outcomes.  The details of these tests are described below. 
 
Anthropometric measures  
Barefoot standing height was measured to the nearest 0.1 cm with a stadiometer (Seca, 
Chino, CA) and body weight was measured on a balance scale (Tanita Corporation, Arlington 
Heights, IL) with shoes and superfluous outer garments (jackets, etc) removed.   
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Body composition and bone density 
Whole body fat, lean and bone mass was measured by dual emission x-ray 
absorptiometry (DXA) (Hologic QDR 4500A, Bedford, Massachusetts).  Precision for DXA 
measurements of interest are ~1.0 – 2.0% in our laboratories.  Appropriate calibrations were 
performed prior to each test.  DXA scans were analyzed by an experienced technician blinded to 
treatment status.  
 
Muscle strength 
Unilateral quadriceps femoris and hamstring muscle strength was evaluated using a 
Biodex System 3 dynamometer (Shirley, NY).  Knee extension and flexion isokinetic muscle 
torque was evaluated at a speed of 60 degrees per second.  The axis of rotation of the machine 
was aligned with the lateral epicondyle of the femur.  The calf pad was positioned halfway 
between the lateral malleolus of the fibula and lateral epicondyle of the femur, and securely 
attached to the subject using straps.  Straps were placed over the thighs, pelvis, and torso regions 
to minimize movement during the test.  Participants performed two sets of 6 repetitions, with a 3-
minute rest between sets, and the best effort was used for analysis.  For all tests, participants 
were verbally encouraged to perform as vigorously as possible.  
 
Shuttle walk test 
Each subject underwent a shuttle walk test to assess physical performance. This is a 
progressive test in which patients walk over a 10 m course paced by programmed beeps with 
progressively increasing speeds.  The shuttle walk test has been correlated with VO2max and 
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may be more beneficial than the VO2max test in this population due to functional limitations 
such as muscle weakness [177]. 
 
Objective physical performance test  
A five item functional fitness test was used as a second objective evaluation of physical 
function [178].  Five physical function tasks were included: 1) Chair Stand Test where subjects 
were asked to stand from a seated position as many times as possible in 30 seconds, 2) Arm Curl 
Test in which subjects were asked to complete as many arm curls as possible during 30 seconds 
using either a 5 pound dumbbell for females, an 8 pound dumbbell for males, 3) Chair Sit and 
Reach Test that asked subjects to reach forward with both arms to try and touch their extended 
leg to assess flexibility, 4) Shoulder flexibility test where subjects were instructed to try to touch 
their middle fingers behind their back to assess upper body flexibility, and 5) 8 Foot Up-and-Go 
test in which subjects were asked to walk around a cone placed 8 feet away from their chair and 
back again during a timed trial.  
 
Fall risk 
Measurement of standing and balance and gait characteristics occurred in a sub-section of 
participants.  In order to assess balance, subjects were asked to stand on a specialized force 
platform (Bertec Inc, Columbus, OH) for 6 trials (2 with eyes open, 2 with eyes closed, and 2 
while verbally answering unrelated questions). To assess gait characteristics, subjects were asked 
to walk across a specialized gait mat (Gaitrite, Sparta, NJ) for 4 trials (2 while not talking and 2 
while verbally answering unrelated questions).  
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Quality of life (QOL)  
QOL was assessed using a validated Kidney Disease Quality of Life (KDQOL
TM
) 
questionnaire [179].   
 
Cardiovascular measurements 
 Blood pressure was measured in duplicate using an automated cuff following a 10min 
quiet rest (Omron IntelliSense HEM-907XL, Lake Forest, IL).  Central pressures were estimated 
from the radial wave form using a validated transfer function by tonometry (SphygmoCor, AtCor 
Medical, Sydney, Australia). 
Aortic PWV was determined by tonometry (SphygmoCor, AtCor Medical, Sydney, 
Australia). In short, Aortic PWV was calculated as the time delay (Δt) between the R-wave of 
the ECG and the foot of the forward pressure wave form (Intersecting Tangent) between the 
carotid and femoral arteries using the equation: PWV= D/Δt (m/sec); where D is distance in 
meters and Δt is the time interval in seconds [180].  D was calculated by subtracting the distance 
between the sternal notch and the location the carotid pressure was measured from the distance 
between the sternal notch and the location the femoral pressure was measured. 
 
Dietary recall   
Subjects completed a 24-hour food recall interview with a registered dietitian using the 
USDA 5-pass method at baseline and at the end of the 6-month intervention period [181].  Two 
interviews were conducted at each time point, a dialysis day and a non-dialysis day, to account 
for variations in eating patterns associated with days of the week.   
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Physical activity recall 
 A seven-day physical activity recall was used to estimate average daily energy 
expenditure [182]. 
  
Blood Markers 
 Blood was collected from each subject at baseline and 6 months for measurement 
standard clinical lab parameters and of inflammatory markers.  Plasma and serum were collected 
by centrifugation and stored at -80°C until analyzed.  Standard clinical lab parameters were 
analyzed by Spectra Laboratories, a renal specific laboratory service provider (Rockleigh, NJ).  
Plasma C-reactive protein (CRP) was measured in duplicate using a commercially available 
ELISA kit (ALPCO Diagnostics, Salem, NH). 
 
Statistical analysis  
Statistical analysis was performed using SPSS Version 22 (IBM, Armonk, NY).  All data 
are presented as mean ± standard deviation, unless otherwise indicated.  Differences in baseline 
characteristics for continuous variables were analyzed with a T-Test.  A Chi-square test was used 
to analyze baseline differences in gender, diabetic and smoking status between groups.  An 
intent-to-treat analysis was performed with repeated measure ANOVA was used to determine 
time by treatment interactions for measurements of interest using all participants who completed 
the 6 month intervention (HMB n=16, Placebo n=17).  Differences in plasma HMB 
concentrations between groups were analyzed using repeated measures ANOVA.  After analysis 
of plasma HMB levels, a per-protocol analysis was performed by repeated measures ANOVA 
using only participants in the HMB group with elevated levels of HMB (n=11).  In both 
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analyses, when ANOVA indicated a main effect, protected LSD was used for pair-wise 
comparisons.  For all statistical tests, significance was determined with a 5 percent chance of 
type 1 error.   
 
Sample Size Determination 
No previous studies have examined the effect of HMB supplementation on lean mass or 
physical function in hemodialysis patients.  In addition, many previous studies in clinical 
populations used less precise measurements of lean mass, such as BIA or skin folds.  Therefore, 
we performed a power analysis based on changes in lean mass, as measured by Bod Pod, from a 
published study in AIDS patients.  Clark et al. [12] supplemented AIDS patients with either 3g 
HMB or a placebo for 8 weeks and observed a 2.55 ± 0.75 kg (mean ± SEM) increase in lean 
mass in the HMB group and a 0.70 ± 0.69 kg loss in lean mass in the placebo group, d = 1.02.  
Based on this study, we have determined that with α=0.05 and β=0.2, we will need 
approximately 15 patients per group to observe significant changes in lean mass between groups 
over time.  We anticipated patient dropout due to extended illness or significant hospitalization 
based on previous studies in our lab.  To accommodate a 20 - 25% drop-out rate, we aimed to 
recruit approximately 20 subjects to each group with the expectation that at least 15 subjects in 
each group would complete all testing.  
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Results: 
Study population 
 MHD patients were recruited from hemodialysis clinics in Champaign and Chicago, IL.  
Details of study recruitment and enrollment can be found in Figure 1.  In total, 33 participants 
(n=17 placebo, n=16 HMB) completed the 6 month intervention.  The causes of end-stage renal 
disease in these patients were type 2 diabetes (n=14), hypertension (n=16), glomerular nephritis 
(n=2), and unknown (n=1).  There were no significant differences between groups in participant 
demographics at baseline (Table 1).  In addition, patient perception of their assigned group did 
not differ between groups (p=0.895), suggesting that participant blinding was adequate. 
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Figure 1. Study enrollment tree. 
 
 
 
 
 
Table 1. Participant characteristics 
 
 
  
Demographics 
Placebo 
(n=17) 
HMB 
(n=16) 
P-value 
Age (years) 53 (13) 57 (8) 0.262 
Gender (male/female) 8 / 9 11 / 5 0.208 
Smoking (%) 35.2 % 43.8 % 0.619 
Diabetes (%) 70.6 % 43.8 % 0.119 
Dialysis Vintage (months) 58 (35) 43 (44) 0.315 
BMI (kg/m
2
) 30.8 (6.4) 31.9 (7.0) 0.664 
Albumin
 
(g/dl)
 
4.0 (0.3) 3.8 (0.5) 0.134 
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Intent to treat analysis: 
 No group x time interaction was observed in any measure of body composition, bone 
density, physical function, or balance and gait parameters (Tables 2-4).  However, a trend for 
improvement with the placebo was observed for sway velocity during standing balance in the 
dual task condition (p=0.074) and a trend for an increase in stride length during the normal walk 
condition with HMB supplementation was observed (p=0.054).  There was a main effect of time 
for an improvement in sway velocity during the eyes closed condition and 95 percent ellipse area 
during the eyes open and eyes closed conditions, independent of group (p<0.05 for all). 
No significant group x time interactions were observed in any domain of the quality of 
life questionnaire; however, satisfaction with care significantly declined over time, independent 
of group (p<0.001, Table 5).  Central pulse wave velocity was 9.9 ± 2.2 m/s and 9.8 ± 2.3 m/s in 
the placebo and HMB groups, respectively, at baseline and did not significantly change 
throughout the intervention (p=0.241 for group x time interaction).  No significant differences in 
standard blood lab values were observed (Table 6).  However, blood urea nitrogen significantly 
increased over time independent of group (p=0.016).  Dietary intake and physical activity did not 
differ between groups at baseline; however, there was a significant group x time interaction in 
energy and fat intake throughout the intervention indicating that the HMB group consumed 
fewer calories and protein at the end of the intervention while the placebo group did not change 
(p<0.05 for each, Table 7).  Carbohydrate intake significantly declined over time independent of 
group (p=0.002). 
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Table 2. No significant differences in bone density or body composition were observed.  
 
Measure 
Placebo (n=17) HMB (n=16) 
P-Value
A 
P-Value
B 
Baseline 6 Month Baseline 6 Month 
BMI  
(g/kg
2
) 
30.8 
(6.4) 
30.9 
(6.9) 
31.9 
(7.0) 
31.3 
(6.8) 
0.398 0.447 
Arm Lean Mass 
(kg) 
6.79  
(1.76) 
6.81 
(1.30) 
7.18 
(2.05) 
7.29 
(2.07) 
0.717 0.623 
Leg Lean Mass 
(kg) 
18.27 
(4.61) 
17.96 
(4.02) 
19.02 
(5.02) 
18.82 
(4.82) 
0.745 0.153 
Appendicular Lean 
Mass (kg) 
25.06 
(5.97) 
24.78 
(5.18) 
26.19 
(6.93) 
26.11 
(6.77) 
0.657 0.421 
Whole Body Lean 
Mass (kg) 
57.78 
(11.65) 
57.58 
(10.04) 
62.04 
(13.24) 
62.32 
(13.27) 
0.610 0.928 
Whole Body Fat 
Mass (kg) 
26.61 
(13.40) 
26.50 
(13.26) 
30.33 
(12.67) 
30.76 
(13.01) 
0.602 0.760 
Whole Body 
Percent Fat (%) 
30.13 
(10.74) 
30.00 
(9.84) 
31.84 
(6.78) 
32.08 
(6.75) 
0.673 0.902 
Bone Mineral 
Content (kg) 
2.37 
(0.62) 
2.37 
(0.62) 
2.38 
(0.45) 
2.36 
(0.43) 
0.520 0.167 
Bone Mineral 
Density (g/cm
2
) 
1.14 
(0.15) 
1.14 
(0.15) 
1.10 
(0.12) 
1.10 
(0.11) 
0.468 0.229 
A: time*treatment interaction; B: main effect of time  
 
Table 3. No significant changes in physical function were observed with supplementation. 
 
Measure 
Placebo (n=17) HMB (n=16) 
P-Value
A 
P-Value
B 
Baseli
ne 
6 Month Baseline 6 Month 
Gait Speed  
(m/s) 
0.91  
(0.30) 
0.92  
(0.28) 
0.93  
(0.23) 
0.98  
(0.17) 
0.282 0.161 
Shuttle Walk Test 
(s) 
272  
(119) 
255  
(113) 
228  
(85) 
232  
(94) 
0.085 0.306 
Chair Stand  
(n) 
11.6  
(4.0) 
10.9  
(4.2) 
10.2  
(3.6) 
10.2  
(3.1) 
0.426 0.426 
Arm Curl  
(n) 
16.9  
(10.4) 
17.4  
(8.8) 
17.3  
(5.5) 
18.4  
(3.7) 
0.681 0.293 
Sit and Reach  
(in) 
-2.3  
(3.6) 
-2.7  
(3.7) 
-2.5  
(3.5) 
-2.6  
(4.7) 
0.707 0.655 
Shoulder Flexibility 
(in) 
-3.7  
(4.8) 
-5.5  
(5.6) 
-7.3  
(5.8) 
-6.2  
(7.0) 
0.193 0.761 
Up and Go  
(s) 
6.6  
(2.9) 
7.0  
(3.1) 
7.1  
(2.1) 
6.7  
(4.9) 
0.434 0.989 
Peak Knee 
Extension (Ft/lb) 
79.7  
(36.6) 
75.9  
(32.5) 
83.6  
(26.7) 
84.4  
(32.2) 
0.335 0.521 
Peak Knee  
Flexion (Ft/lb) 
40.9  
(22.0) 
38.8  
(19.1) 
37.9  
(12.2) 
40.2  
(15.4) 
0.169 0.948 
A: time*treatment interaction; B: main effect of time  
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Table 4. There were no significant differences between groups in standing balance or gait 
parameters throughout the intervention. 
 
Measure 
Placebo
C 
HMB
D 
P-Value
A 
P-Value
B 
Baseline 6 Month Baseline 6 Month 
 
Force Plate Variables   
  
Ellipse Area –  
Eyes Open (cm
2
) 
12.59 
(18.70) 
10.10 
(6.35) 
6.24 
(9.12) 
3.02 
(1.44) 
0.849 0.149 
Ellipse Area –  
Eyes Closed (cm
2
) 
7.45 
(3.84) 
5.17 
(4.67) 
5.12 
(3.16) 
4.25 
(3.03) 
0.345 0.048 
Ellipse Area –  
Dual Task (cm
2
) 
3.64 
(3.15) 
4.26 
(3.58) 
5.27 
(5.22) 
5.26 
(4.76) 
0.663 0.673 
Velocity –  
Eye Open (cm/s) 
3.41 
(1.80) 
2.59 
(1.70) 
2.94 
(0.95) 
2.42 
(0.77) 
0.347 <0.001 
Velocity –  
Eyes Closed (cm/s) 
3.24 
(0.65) 
2.50 
(1.06) 
3.81 
(1.49) 
3.29 
(1.15) 
0.550 0.003 
Velocity –  
Dual Task (cm/s) 
2.68 
(0.43) 
2.18 
(1.07) 
2.81 
(0.82) 
2.83 
(0.95) 
0.074 0.103 
 
Gait Mat Variables 
      
Stride Length –  
Normal Walk (cm) 
126.76 
(18.26) 
121.89 
(14.88) 
121.50 
(22.22) 
124.10 
(20.46) 
0.054 0.545 
Stride Length –  
Dual Task (cm) 
118.94 
(18.95) 
122.08 
(27.23) 
111.70 
(20.39) 
114.38 
(19.21) 
0.902 0.130 
 
Single Support –  
Normal Walk (%) 
34.12 
(2.27) 
34.14 
(2.42) 
33.80 
(2.76) 
33.58 
(4.12) 
0.782 0.820 
Single Support –  
Dual Task (%) 
33.07 
(2.41) 
33.31 
(4.11) 
32.53 
(3.28) 
32.72 
(3.06) 
0.958 0.627 
Double Support –  
Normal Walk (%) 
31.73 
(4.44) 
31.89 
(5.30) 
32.56 
(5.49) 
33.27 
(8.26) 
0.769 0.643 
Double Support –  
Dual Task (%) 
34.50 
(5.76) 
34.56 
(7.30) 
35.18 
(7.95) 
34.94 
(7.05) 
0.831 0.901 
Velocity –  
Normal Walk (cm/s) 
110.00 
(18.38) 
103.43 
(14.68) 
104.01 
(26.93) 
107.13 
(27.27) 
0.093 0.537 
Velocity –  
Dual Task (cm/s) 
93.68 
(15.54) 
90.41 
(19.14) 
89.56 
(24.07) 
91.50 
(25.46) 
0.225 0.753 
Cadence –  
Normal Walk 
(steps/min) 
104.27 
(10.40) 
101.70 
(7.52) 
102.03 
(10.52) 
102.75 
(9.55) 
0.321 0.575 
Cadence –  
Dual Task (steps/min) 
95.10 
(8.64) 
90.30 
(11.51) 
95.69 
(14.96) 
94.84 
(13.18) 
0.353 0.189 
Swing Time –  
Normal Walk (%CV) 
3.57 
(1.43) 
4.27 
(2.25) 
9.11 
(9.04) 
11.30 
(11.65) 
0.478 0.179 
Swing Time –  
Dual Task (%CV) 
6.38 
(5.14) 
10.62 
(13.41) 
12.93 
(10.70) 
11.51 
(11.04) 
0.199 0.516 
A: time*treatment interaction; B: main effect of time; C: force plate variables (n=8), gait mat variables (n=10); D: 
force plate variables (n=10), gait mat variables (n=13); CV: coefficient of variance 
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Table 5. No significant differences in quality of life were observed between groups, but 
patient satisfaction with care was reduced over time, independent of group. 
 
Measure 
Placebo (n=17) HMB (n=16) 
P-Value
A 
P-Value
B 
Baseline 6 Month Baseline 6 Month 
Burden 57.7 (27.6) 64.0 (28.8) 58.2 (30.9) 64.1 (27.9) 0.962 0.150 
Cognitive 88.2 (16.6) 85.1 (18.9) 88.3 (13.9) 82.5 (23.1) 0.633 0.119 
Social 82.4 (16.7) 81.2 (20.3) 82.5 (19.3) 79.6 (23.7) 0.784 0.521 
Symptom 78.2 (16.8) 78.4 (16.2) 85.7 (9.4) 83.5 (10.7) 0.572 0.650 
CKD Effect 73.5 (23.4) 72.1 (21.9) 74.6 (22.5) 74.4 (19.0) 0.860 0.818 
Sleep 64.0 (24.4) 64.9 (23.4) 59.8 (21.7) 63.8 (23.7) 0.649 0.472 
Support 82.4 (19.1) 78.4 (24.8) 77.1 (26.4) 84.4 (17.7) 0.205 0.700 
Work Status 6.8 (16.4) 6.9(16.6) 32.1 (35.7) 32.1 (40.0) 0.994 0.994 
Satisfaction
C
  69.6 (17.9) 56.9 (22.9) 81.3 (19.1) 62.5 (25.5) 0.458 < 0.001 
Encouragement
D 77.9 (22.3) 67.6 (36.5) 73.4 (35.9) 86.7 (15.5) 0.058 0.805 
A: time*treatment interaction; B: main effect of time; C: satisfaction with care; D: staff encouragement 
 
Table 6. No significant differences were observed in concentrations of standard lab 
values. 
 
Measure 
Placebo (n=17) HMB (n=16) 
P-Value
A 
P-Value
B 
Baseline 6 Month Baseline 6 Month 
Potassium 
(mEq/L) 
4.5  
(0.6) 
4.8  
(0.6) 
4.9  
(0.6) 
5.1  
(0.6) 
0.587 0.064 
Calcium  
(mg/dL) 
9.3  
(1.1) 
9.1  
(0.8) 
8.9  
(1.3) 
9.9  
(3.6) 
0.304 0.498 
Phosphorous 
(mg/dL) 
5.2  
(1.5) 
4.9  
(1.0) 
6.0  
(1.9) 
5.3  
(1.8) 
0.558 0.119 
Albumin  
(g/dL) 
4.0  
(0.3) 
4.0  
(0.4) 
3.8  
(0.5) 
3.9  
(0.4) 
0.231 0.381 
BUN  
(mg/dL) 
49.9  
(16.0) 
53.3  
(15.9) 
56.7  
(20.8) 
68.5  
(21.7) 
0.180 0.019 
Creatinine 
(mg/dL) 
9.3  
(3.8) 
10.0  
(4.0) 
8.9  
(2.7) 
9.6  
(2.6) 
0.961 0.084 
Hemoglobin 
(g/dL) 
10.9  
(1.0) 
11.1  
(1.2) 
11.3  
(1.1) 
11.1  
(1.1) 
0.623 0.997 
Hematocrit  
(%) 
34.5  
(3.1) 
34.3  
(3.9) 
34.9  
(3.5) 
34.6  
(3.1) 
0.943 0.784 
WBC  
(1000/μL) 
5.5  
(1.5) 
5.4  
(1.2) 
5.7  
(2.2) 
5.9  
(2.4) 
0.622 0.983 
CRP  
(mg/dl) 
8.9  
(9.0) 
11.2  
(10.8) 
11.2  
(15.4) 
10.4  
(10.9) 
0.409 0.675 
A: time*treatment interaction; B: main effect of time; BUN: blood urea nitrogen; WBC: White Blood Cell;  
CRP: C-reactive protein 
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Table 7. Changes in energy and fat consumption throughout the intervention differed 
between groups. 
 
Measure 
Placebo (n=17) HMB (n=16) 
P-Value
A 
P-Value
B 
Baseline 6 Month Baseline 6 Month 
Energy Consumed 
(kcal/day) 
1795 
(482) 
1843  
(850) 
2154 
(1069) 
1578 
(625) 
0.044 0.087 
Energy Consumed 
(kcal/kg/day) 
21.7  
(4.8) 
22.9  
(10.8) 
24.4 
(12.7) 
17.7 
(9.7) 
0.025 0.118 
Protein Consumed 
(g/day) 
71.5 
(23.8) 
79.6  
(42.6) 
94.3 
(46.1) 
79.5 
(31.8) 
0.146 0.666 
Protein Consumed 
(g/kg/day) 
0.85 
(0.22) 
1.00  
(0.56) 
1.07 
(0.55) 
0.90 
(0.51) 
0.099 0.872 
Carbohydrates 
Consumed (g/day) 
233.3 
(95.3) 
201.9 
(72.0) 
235.7 
(106.5) 
179.9 
(81.4) 
0.357 0.002 
Fat Consumed 
(g/day) 
66.2 
(16.8) 
87.7  
(53.9) 
96.2 
(73.3) 
63.80 
(25.33) 
0.024 0.634 
Energy Expended 
(kcal/kg/day) 
34.47 
(3.75) 
34.18 
(4.68) 
32.47 
(1.08) 
32.15 
(1.26) 
0.970 0.426 
A: time*treatment interaction; B: main effect of time  
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Treatment Compliance  
 Plasma HMB was analyzed through GC-MS, as previously described [174], to assess 
treatment compliance.  Changes in plasma HMB levels of participants in the placebo group 
during the intervention can be seen in Figure 2.  In the HMB group, 11 patients had elevated 
plasma HMB concentrations at 3 and 6 months and were labeled as compliant (Figure 3) while 5 
patients did not have elevated plasma HMB concentrations at 3 and/or 6 months and were 
labeled to be non-compliant (Figure 4).  Based on this data, a per-protocol analysis was 
performed using the 17 participants in the placebo group and 11 compliant HMB participants.  
Mean plasma HMB concentrations significantly differed between groups at 3 and 6 months in 
participants used in the per-protocol analysis (p<0.001 for each, Figure 5).  
 
 
 
 
 
 
 
 
 
 
Figure 2. Plasma HMB concentrations in participants in the placebo group throughout the 
intervention. 
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Figure 3. Plasma HMB concentrations in compliant individuals in the HMB group throughout 
the intervention. 
 
 
 
 
 
 
 
 
 
 
Figure 4. Plasma HMB concentrations in non-compliant individuals in the HMB group 
throughout the intervention. 
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Figure 5. Mean plasma HMB concentrations significantly differed between groups at 3 and 6 
months in participants used in per-protocol analysis (* p<0.001). 
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Per protocol analysis 
 In total, 28 patients were included in the per-protocol analysis (Placebo n=17, HMB 
n=11).  The primary causes of end stage renal disease in these patients were type 2 diabetes 
(n=12), hypertension (n=15), and glomerular nephritis (n=1).  Dialysis vintage was significantly 
lower in the HMB group than the placebo group (p=0.010); however, there were no other 
significant differences in patient characteristics between groups (Table 8).  Perception of group 
assignment was not different between groups (p=0.954) suggesting that participant blinding was 
adequate. 
 
 
Table 8. Participant characteristics in per-protocol analysis 
 
 
  
Demographics 
Placebo 
(n=17) 
HMB 
(n=11) 
P value 
Age (years) 53 (13) 58 (9) 0.253 
Gender (male/female) 8 / 9 7 / 4 0.390 
Smoking (%) 35.2 % 45.5 % 0.591 
Diabetes (%) 70.6 % 63.6 % 0.700 
Dialysis Vintage (months) 58 (35) 30 (16) 0.010 
BMI (kg/m
2
) 30.8 (6.4) 32.1 (7.0) 0.634 
Albumin
 
(g/dl)
 
4.0 (0.3) 3.8 (0.5) 0.159 
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No group x time interaction was observed in any measure of body composition, bone 
density, physical function, or balance and gait parameters (Tables 9-11).  However, a trend for an 
improvement in the chair stand (p=0.094), up-and-go (0.096), and shoulder flexibility tests 
(0.064) were observed with HMB supplementation.  In addition, a trend for an increase in stride 
length during the normal walk condition with HMB supplementation was observed (p=0.052).  
Conversely, a trend for improvement with the placebo was observed for sway velocity during 
standing balance in the dual task condition (p=0.074).  Sway velocity during the eyes closed 
condition and 95 percent ellipse area during the eyes open and eyes closed conditions 
significantly improved over time, independent of group. 
No significant group x time interactions were observed in any domain of the quality of 
life questionnaire; however, satisfaction with care significantly declined over time, independent 
of group (p<0.001, Table 12).  Aortic pulse wave velocity was 9.9 ± 2.2 m/s and 10.6 ± 2.2 m/s 
in the placebo and HMB groups, respectively, at baseline and did not significantly change 
throughout the intervention (p=0.390 for group x time interaction).  No significant differences 
between groups over time were observed in standard lab values (Table 13).  However, creatinine 
significantly increased independent of group (p=0.046).  Dietary intake and physical activity did 
not differ between groups at baseline and no significant group x time interaction was observed in 
any dietary or physical activity measure (Table 14).  However, carbohydrate intake significantly 
declined over time independent of group (p=0.02). 
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Table 9. No significant differences in bone density or body composition were observed.  
 
Measure 
Placebo (n=17) HMB (n=11) 
P-Value
A 
P-Value
B 
Baseline 6 Month Baseline 6 Month 
BMI (g/kg
2
) 
30.8 
(6.4) 
30.9 
(6.9) 
32.1 
(7.0) 
31.1 
(6.1) 
0.200 0.226 
Arm Lean Mass 
(kg) 
6.79  
(1.76) 
6.81 
(1.30) 
6.75 
(1.89) 
6.89 
(1.93) 
0.695 0.614 
Leg Lean Mass 
(kg) 
18.27 
(4.61) 
17.96 
(4.02) 
18.41 
(4.85) 
18.39 
(4.70) 
0.492 0.412 
Appendicular Lean 
Mass (kg) 
25.06 
(5.97) 
24.78 
(5.18) 
25.17 
(6.56) 
25.28 
(6.48) 
0.463 0.740 
Whole Body Lean 
Mass (kg) 
57.78 
(11.65) 
57.58 
(10.04) 
61.03 
(12.54) 
61.86 
(13.11) 
0.340 0.554 
Whole Body Fat 
Mass (kg) 
26.61 
(13.40) 
26.50 
(13.26) 
31.89 
(12.23) 
31.20 
(11.83) 
0.576 0.439 
Whole Body 
Percent Fat (%) 
30.13 
(10.74) 
30.00 
(9.84) 
33.49 
(5.94) 
32.92 
(5.57) 
0.638 0.452 
Bone Mineral 
Content (kg) 
2.37 
(0.62) 
2.37 
(0.62) 
2.43 
(0.47) 
2.42 
(0.46) 
0.736 0.308 
Bone Mineral 
Density (g/cm
2
) 
1.14 
(0.15) 
1.14 
(0.15) 
1.13 
(0.12) 
1.12 
(0.11) 
0.327 0.167 
A: time*treatment interaction; B: main effect of time  
 
 
Table 10. No significant changes in physical function were observed. 
 
Measure 
Placebo (n=17) HMB (n=11) 
P-Value
A 
P-Value
B 
Baseline 6 Month Baseline 6 Month 
Gait Speed  
(m/s) 
0.91  
(0.30) 
0.92  
(0.28) 
0.93  
(0.21) 
1.00  
(0.15) 
0.257 0.144 
Shuttle Walk Test 
(s) 
272  
(119) 
255  
(113) 
215  
(53) 
210  
(63) 
0.358 0.105 
Chair Stand  
(n) 
11.6  
(4.0) 
10.9  
(4.2) 
8.9  
(2.0) 
9.7  
(2.0) 
0.094 0.851 
Arm Curl  
(n) 
16.9  
(10.4) 
17.4  
(8.8) 
17.3  
(6.7) 
18.0  
(3.9) 
0.891 0.488 
Sit and Reach  
(in) 
-2.3  
(3.6) 
-2.7  
(3.7) 
-2.9  
(4.2) 
-2.8  
(5.1) 
0.641 0.784 
Shoulder Flexibility 
(in) 
-3.7  
(4.8) 
-5.5  
(5.6) 
-8.7  
(5.1) 
-5.7  
(8.3) 
0.064 0.637 
Up and Go  
(s) 
6.6  
(2.9) 
7.0  
(3.1) 
7.3  
(2.2) 
5.8  
(4.7) 
0.096 0.351 
Peak Knee 
Extension (Ft/lb) 
79.7  
(36.6) 
75.9  
(32.5) 
83.4  
(28.4) 
86.4  
(33.7) 
0.212 0.872 
Peak Knee  
Flexion (Ft/lb) 
40.9  
(22.0) 
38.8  
(19.1) 
38.0  
(12.8) 
40.8  
(16.0) 
0.194 0.834 
A: time*treatment interaction; B: main effect of time 
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Table 11. There were no significant differences between groups in standing balance or gait 
parameters throughout the intervention. 
 
Measure 
Placebo
C 
HMB
D 
P-Value
A 
P-Value
B 
Baseline 6 Month Baseline 6 Month 
 
Force Plate Variables   
  
Ellipse Area –  
Eyes Open (cm
2
) 
12.59 
(18.70) 
10.10 
(6.35) 
3.62 
(1.60) 
3.30 
(1.38) 
0.450 0.333 
Ellipse Area –  
Eyes Closed (cm
2
) 
7.45 
(3.84) 
5.17 
(4.67) 
5.23 
(2.79) 
3.49 
(1.06) 
0.747 0.038 
Ellipse Area –  
Dual Task (cm
2
) 
3.64 
(3.15) 
4.26 
(3.58) 
6.77 
(5.94) 
5.99 
(5.56) 
0.395 0.923 
Velocity –  
Eye Open (cm/s) 
3.41 
(1.80) 
2.59 
(1.70) 
2.85 
(1.18) 
2.41 
(0.97) 
0.337 0.005 
Velocity –  
Eyes Closed (cm/s) 
3.24 
(0.65) 
2.50 
(1.06) 
3.90 
(1.63) 
3.37 
(1.36) 
0.612 0.007 
Velocity –  
Dual Task (cm/s) 
2.68 
(0.43) 
2.18 
(1.07) 
2.85 
(1.00) 
2.99 
(1.14) 
0.072 0.282 
 
Gait Mat Variables 
      
Stride Length –  
Normal Walk (cm) 
126.76 
(18.26) 
121.89 
(14.88) 
115.31 
(17.73) 
119.02 
(15.51) 
0.052 0.783 
Stride Length –  
Dual Task (cm) 
118.94 
(18.95) 
122.08 
(27.23) 
105.65 
(16.75) 
109.85 
(15.97) 
0.799 0.088 
Single Support –  
Normal Walk (%) 
34.12 
(2.27) 
34.14 
(2.42) 
33.07 
(2.25) 
32.77 
(4.23) 
0.747 0.780 
Single Support –  
Dual Task (%) 
33.07 
(2.41) 
33.31 
(4.11) 
31.73 
(3.14) 
32.00 
(2.97) 
0.982 0.623 
Double Support –  
Normal Walk (%) 
31.73 
(4.44) 
31.89 
(5.30) 
34.08 
(4.40) 
35.07 
(8.32) 
0.699 0.592 
Double Support –  
Dual Task (%) 
34.50 
(5.76) 
34.56 
(7.30) 
36.85 
(8.07) 
36.55 
(7.02) 
0.823 0.884 
Velocity –  
Normal Walk (cm/s) 
110.00 
(18.38) 
103.43 
(14.68) 
96.57 
(21.25) 
100.20 
(17.89) 
0.111 0.635 
Velocity –  
Dual Task (cm/s) 
93.68 
(15.54) 
90.41 
(19.14) 
82.45 
(21.46) 
85.35 
(23.12) 
0.193 0.936 
Cadence –  
Normal Walk (steps/min) 
104.27 
(10.40) 
101.70 
(7.52) 
100.20 
(10.30) 
100.89 
(5.97) 
0.371 0.603 
Cadence –  
Dual Task (steps/min) 
95.10 
(8.64) 
90.30 
(11.51) 
93.36 
(16.40) 
92.27 
(13.65) 
0.443 0.228 
Swing Time –  
Normal Walk (%CV) 
3.57 
(1.43) 
4.27 
(2.25) 
10.86 
(9.68) 
13.85 
(12.23) 
0.334 0.129 
Swing Time –  
Dual Task (%CV) 
6.38 
(5.14) 
10.62 
(13.41) 
15.84 
(10.54) 
14.11 
(11.41) 
0.238 0.615 
A: time*treatment interaction; B: main effect of time; C: force plate variables (n=8), gait mat variables (n=10); D: 
force plate variables (n=6), gait mat variables (n=10); CV: coefficient of variance 
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Table 12. Patient satisfaction with care was significantly reduced over time, but no 
significant differences in quality of life were observed between groups. 
 
Measure 
Placebo (n=17) HMB (n=11) 
P-Value
A 
P-Value
B 
Baseline 6 Month Baseline 6 Month 
Burden 57.7 (27.6) 64.0 (28.8) 58.0 (25.6) 67.0 (26.5) 0.765 0.115 
Cognitive 88.2 (16.6) 85.1 (18.9) 90.9 (12.0) 81.8 (24.4) 0.334 0.053 
Social 82.4 (16.7) 81.2 (20.3) 87.3 (16.5) 77.0 (26.6) 0.187 0.100 
Symptom 78.2 (16.8) 78.4 (16.2) 85.6 (9.9) 83.1 (10.8) 0.607 0.673 
CKD Effect 73.5 (23.4) 72.1 (21.9) 78.1 (12.3) 74.7 (19.1) 0.813 0.552 
Sleep 64.0 (24.4) 64.9 (23.4) 60.7 (23.4) 63.2 (28.4) 0.832 0.658 
Support 82.4 (19.1) 78.4 (24.8) 84.8 (18.9) 87.9 (16.8) 0.472 0.926 
Work Status 6.8 (16.4) 6.9(16.6) 32.5 (40.1) 37.1 (44.8) 0.595 0.586 
Satisfaction
C
  69.6 (17.9) 56.9 (22.9) 84.8 (15.7) 60.6 (27.2) 0.209 <0.001 
Encouragement
D 77.9 (22.3) 67.6 (36.5) 81.8 (25.2) 87.5 (12.5) 0.153 0.675 
A: time*treatment interaction; B: main effect of time; C: satisfaction with care; D: staff encouragement 
 
Table 13. No significant differences were observed in concentrations of standard lab 
values. 
 
Measure 
Placebo (n=17) HMB (n=11) 
P-Value
A 
P-Value
B 
Baseline 6 Month Baseline 6 Month 
Potassium  
(mEq/L) 
4.5  
(0.6) 
4.8  
(0.6) 
4.9  
(0.6) 
5.1  
(0.7) 
0.760 0.079 
Calcium  
(mg/dL) 
9.3  
(1.1) 
9.1  
(0.8) 
9.3  
(0.6) 
9.2  
(1.0) 
0.850 0.573 
Phosphorous  
(mg/dL) 
5.2  
(1.5) 
4.9  
(1.0) 
5.8  
(2.1) 
5.4  
(1.9) 
0.921 0.307 
Albumin  
(g/dL) 
4.0  
(0.3) 
4.0  
(0.4) 
3.8  
(0.6) 
3.9  
(0.4) 
0.334 0.501 
BUN  
(mg/dL) 
49.9  
(16.0) 
53.3  
(15.9) 
61.8  
(18.4) 
68.0  
(25.3) 
0.622 0.105 
Creatinine  
(mg/dL) 
9.3  
(3.8) 
10.0 
 (4.0) 
8.4  
(2.4) 
9.5  
(2.7) 
0.578 0.046 
Hemoglobin  
(g/dL) 
10.9  
(1.0) 
11.1  
(1.2) 
11.1  
(0.7) 
10.7  
(1.0) 
0.389 0.679 
Hematocrit  
(%) 
34.5  
(3.1) 
34.3  
(3.9) 
34.4  
(2.9) 
33.5  
(3.0) 
0.735 0.611 
WBC  
(1000/μL) 
5.5  
(1.5) 
5.4  
(1.2) 
6.4  
(1.6) 
6.5  
(2.5) 
0.676 0.965 
CRP  
(mg/dl) 
8.9  
(9.0) 
11.2  
(10.8) 
14.1  
(17.6) 
13.2  
(11.8) 
0.484 0.738 
A: time*treatment interaction; B: main effect of time; BUN: blood urea nitrogen; WBC: white blood cells;  
CRP: C-reactive protein 
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Table 14. Changes in diet and physical activity levels during the intervention did not 
differ between groups. 
 
Measure 
Placebo (n=17) HMB (n=11) 
P-Value
A 
P-Value
B 
Baseline 6 Month Baseline 6 Month 
Energy Consumed 
(kcal/day) 
1795 
(482) 
1843  
(850) 
1713 
(754) 
1370 
(566) 
0.197 0.215 
Energy Consumed 
(kcal/kg/day) 
21.7  
(4.8) 
22.9  
(10.8) 
19.2 
(9.0) 
14.5 
(5.5) 
0.099 0.221 
Protein Consumed 
(g/day) 
71.5 
(23.8) 
79.6  
(42.6) 
78.3 
(32.3) 
65.6 
(25.2) 
0.337 0.566 
Protein Consumed 
(g/kg/day) 
0.85 
(0.22) 
1.00  
(0.56) 
0.90 
(0.44) 
0.70 
(0.24) 
0.145 0.581 
Carbohydrates 
Consumed (g/day) 
233.3 
(95.3) 
201.9 
(72.0) 
196.0 
(92.3) 
156.1 
(80.2) 
0.681 0.020 
Fat Consumed 
(g/day) 
66.2 
(16.8) 
87.7  
(53.9) 
69.1 
(40.9) 
57.8 
(22.1) 
0.112 0.724 
Energy Expended 
(kcal/kg/day) 
34.47 
(3.75) 
34.18 
(4.68) 
32.3 
(1.25) 
31.9 
(1.26) 
0.869 0.448 
A: time*treatment interaction; B: main effect of time  
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Discussion: 
 Supplementation of beta-hydroxy-beta-methylbutyrate (HMB) has been previously 
shown to attenuate muscle loss in catabolic populations such as cancer patients [11], AIDS 
patients [12], and the elderly [10].  Maintenance hemodialysis (MHD) patients represent another 
catabolic population that could benefit from HMB supplementation; however, the present study 
does not support its efficacy.  Supplementation with HMB for 6 months did not improve any 
marker of body composition, strength, physical function, balance and gait parameters, quality of 
life, or inflammation in either intent-to-treat or per-protocol analysis.  However, it should be 
noted that the per-protocol analysis was underpowered and trends for improvement of markers of 
physical function (chair stand, up-and-go test, and shoulder flexibility) were observed with HMB 
supplementation in this analysis. 
 MHD patients are a catabolic population reported to lose as much as 1-3 kg lean mass 
annually [2].  Previous nutritional interventions aimed at attenuating this rapid decline in muscle 
mass have been largely unsuccessful [112, 113, 116].  HMB has been shown to increase muscle 
mass in other catabolic populations.  Increases of 0.5kg and 0.55kg after six months [183] and 
one year [10], respectively, in the elderly, 2.6kg in 8 weeks in AIDS patients [12], and 1kg in 24 
wks in cancer patients [11] have been observed.  Moreover, HMB attenuated muscle loss during 
10 days of bed rest in the elderly [184].  However, in the present study, no significant changes in 
whole body or regional lean mass were observed after 6 months of HMB supplementation in 
either intent-to-treat or per-protocol analysis.  This finding is similar to previous studies in 
gastric bypass [154] and rheumatoid arthritis patients [153] which also did not observe changes 
in lean mass with HMB supplementation.  A potential limitation lean body mass assessment in 
the present study is that interdialytic fluid shifts in MHD patients may have affected the accuracy 
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of DXA measurements [185].  However, all patients were tested 18-24hrs following 
hemodialysis treatment.  In addition, all baseline and 6 month testings were performed on the 
same day of the week at the same time of day to account for fluid changes.   
 In addition to loss of skeletal muscle mass, MHD patients have been shown to have 
reduced strength compared to age-matched healthy controls [5, 23, 99].  HMB has been 
previously shown to improve muscle strength in the elderly in 12 weeks [142, 183]; however, in 
the current study no changes in quadriceps or hamstring muscle strength were observed with 
HMB supplementation in either intent-to-treat or per-protocol analysis.  One previous study 
suggested that changes in muscle strength with HMB supplementation may be vitamin D 
dependent [143].  Vitamin D deficiency is prevalent in as many as 92 percent of MHD patients 
and as a result a majority of patients receive supplemental vitamin D as part of standard care 
[186].  However, in the present study, we were unable to control for changes in vitamin D 
prescription throughout the intervention which may have effected changes in muscle strength 
observed in this intervention.  In addition, it should also be noted that increases in strength have 
not been observed in all previous studies with HMB in elderly and clinical populations.  Marcora 
et al. [153] supplemented rheumatoid arthritis patients with either HMB or placebo for 12 weeks 
and did not observe an increase in handgrip, elbow flexor, or knee extensor strength suggesting 
that HMB may not increase muscle strength in all clinical populations.   
 The effects of HMB supplementation on physical function in elderly and clinical 
populations have provided mixed results.  Flakoll et al. [142] observed an increase in up-and-go 
test time after 12 weeks of HMB supplementation in the elderly; however, Marcora et al. [153] 
did not observe any change in sit-to-stand test following 12 weeks of HMB supplementation in 
rheumatoid arthritis patients.  In MHD patients, physical function is reduced compared to healthy 
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controls, even in high functioning MHD patients [99]; therefore, interventions to improve 
physical function are needed in this population.  After 6 months of HMB supplementation in 
MHD patients, no significant change was observed in any measurement of physical function in 
the intent-to-treat analysis.  However, a trend for improvements in chair stand, up-and-go, and 
shoulder flexibility tests were observed with HMB supplementation in the per-protocol analysis.  
It should be noted that although the intent-to-treat analysis was adequately powered, the per-
protocol analysis was slightly underpowered.  Therefore, it is possible these trends may have 
been significant given adequate statistical power.  Future studies are needed to conclusively 
determine the effects of HMB supplementation on physical function in MHD patients. 
 MHD patients have a greater postural sway [187], worse gait [188], and an increased dual 
task cost [100] compared to age, gender, and BMI matched healthy controls.  This results in a 
significantly elevated fall risk and contributes to a hip fracture risk of around 4-fold higher than 
the general population [189, 190].  Previous interventions with HMB in elderly and clinical 
populations have not examined the effects of HMB supplementation on fall risk.  In the present 
study, we did not observe any significant differences in any balance or gait parameter measured.  
However, a limitation of this analysis is that it was only performed on a subsection of 
participants limiting statistical power.  In addition, several force plate variables significantly 
improved over time in both the intent-to-treat and per-protocol analysis, regardless of group, 
suggesting a learning effect.  Although the present study does not support the use of HMB for 
fall risk prevention in MHD patients, future studies are needed examine interventions to decrease 
falls in this high-risk population. 
 Quality of Life is significantly lower in hemodialysis patients than in the general 
population [105].  Previous studies examining the effects of HMB on quality of life in clinical 
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and elderly populations have primarily shown no effect [10, 11, 153].  Similarly, using a quality 
of life questionnaire previously validated in kidney disease patients [179], we did not observe a 
group x time interaction in any domain of the quality of life questionnaire.  However, we 
observed a significant decrease in satisfaction with care over time, independent of group, in both 
intent-to-treat and per-protocol analysis suggesting that patient dislike for hemodialysis treatment 
increases the longer they are on dialysis.   
Although a previous short-term study did not observe any adverse effects of HMB 
supplementation [14], the long-term safety of HMB supplementation has previously not been 
determined in MHD patients.  In the present study, we did not observe any significant 
differences in standard plasma laboratory measures between patients supplemented with HMB or 
placebo.  However, it is possible that the additional calcium in the calcium-HMB supplement 
may result in negative effects on arterial health.  Use of calcium based phosphate binders 
(approximately 1.5g calcium/day from binders) has been shown to result in increased vascular 
calcification [191].  However, it is unclear if the approximately 400 mg calcium present in the 
calcium HMB supplement exhibits similar effects on the vasculature. In addition, it should be 
noted that large scale clinical trials have not observed a survival benefit in patients taking non-
calcium based phosphate binders compared with those receiving calcium based phosphate 
binders (as reviewed by [192]).  To address these concerns we measured aortic pulse wave 
velocity, a measure of arterial stiffness, and standard blood laboratory measures of calcium and 
phosphorous at baseline and after 6 months of the intervention.  No significant differences in 
arterial stiffness or standard lab parameters were observed throughout the intervention 
suggesting that HMB supplementation did not result in increased vascular calcification and 
arterial stiffness in MHD patients. 
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 There are several potential reasons for the discrepancies in results between the beneficial 
effects of HMB observed in many of the previous studies in elderly and clinical populations and 
the lack of effect of HMB in the current study.  First, many of the studies the observed beneficial 
effects of HMB supplementation on lean mass, strength, and physical function supplemented 
with a cocktail of HMB along with other amino acids [10-12, 142, 143] while we supplemented 
with HMB alone.  The absence of additional amino acids in our supplementation protocol may 
have contributed to differences in outcomes.  However, not all studies supplementing a cocktail 
of HMB and amino acids in elderly and clinical populations have observed beneficial effects of 
supplementation [153, 154].  In addition, supplementation of HMB alone has been found to 
increase lean mass and strength in 24 weeks in the elderly [183],  preserve muscle mass during 
10 days of bed rest in the elderly [184], reduce inflammation in patients with chronic obstructive 
pulmonary disease [152], reduce nitrogen loss in elderly patients in the intensive care unit 
receiving tube feeding [140], attenuate lean mass loss and strength loss in animal models of 
aging [193] and unloading [157], and activate anabolic pathways while inhibiting catabolic 
pathways in skeletal muscle (as reviewed by [13]).  Therefore, it is unlikely that the absence of 
amino acids in the supplementation cocktail in the current study affected study results. 
 MHD patients in the present study were not as catabolic as previously reported in this 
population.  Pupim et al. observed a mean reduction of lean mass of 1.1 kg in non-diabetic and  
3.4 kg in malnourished (average albumin 3.4 g/dl) MHD patients during the first year of dialysis 
[2].  However, in the placebo group we observed a 0.2 kg reduction in lean mass in 6 months 
with a mean albumin of 4.0 g/dl.  Therefore, it is possible that better nutritional status in our 
population did not allow us to observe significance in outcomes of interest over the study period.   
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Patients in this study were instructed to maintain dietary and physical activity patterns 
throughout the study.  However, in the intent-to-treat analysis there was a group x time 
interaction for a reduction in energy and fat intake with a trend for a reduction in protein intake 
in the HMB group.  There was also a significant reduction in carbohydrate intake over time 
regardless of group.  In the per-protocol analysis, there were no significant group x time 
interactions in nutrient intake or energy expenditure; however, the significant reduction in 
carbohydrate intake over time, independent of group remained.  It is possible that the reductions 
in calorie and protein intake in the HMB group over the course of the intervention blunted 
potential benefits from HMB supplementation.  In addition, we were unable to control for 
changes in medication or dialysis prescription during the study period which may have affected 
outcomes.   
 Although no effect of HMB supplementation on lean mass was observed in the present 
study, single nutrient interventions to combat lean mass in MHD patients have primarily shown 
no effect [112, 113, 116, 176].  Moreover, recent randomized clinical trials assessing the effects 
of either resistance and/or endurance exercise training on metrics related to physical function, 
body composition, and CVD risk have been somewhat equivocal [8, 84, 194-197].  This is likely 
due to the complex nature of muscle loss in this population resulting from a number of causes 
such as: metabolic acidosis, inflammation, insulin resistance, decreased nutrient intake, hormonal 
abnormalities, an elevated metabolic rate, and loss of amino acids into the dialysate (as reviewed 
by [30, 31]).  Future interventions in this population likely need to provide a more 
comprehensive approach in order to successfully attenuate muscle loss in MHD patients. 
 A limitation of this study is the small sample size in this intervention.  Initial power 
analysis indicated a sample size of at least 15 patients per group would be needed in order to 
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have appropriate power to detect changes in lean mass.  Therefore, the intent-to-treat protocol in 
this study was adequately powered with n=16 HMB and n=17 placebo.  However, it was 
discovered that 5 participants in the HMB group were no compliant.  Therefore a per-protocol 
analysis with n=11 HMB and n=17 placebo was run; however, this analysis was underpowered.  
Despite this, we observed trends for improvements in chair stand, up and go test, and shoulder 
flexibility tests in the per-protocol analysis which require further investigation in a study 
appropriately powered with compliant participants. 
 Pill compliance is a major hurdle for clinicians when treating MHD patients.  On average, 
MHD patients take 10-12 different types of medication per day, with a median pill intake 
approximately 19 pills/day [198, 199].  Moreover, 25 percent of patients take over 25 pills daily 
[199].  This high level of pill burden leads to rates of non-compliance with prescription 
medication as high as 50-80 percent, depending upon the method used to measure compliance 
[200].  The non-compliance observed in the HMB group in this study occurred in 31 percent of 
patients which is likely lower than previously reported for prescription drugs due to patients 
being reminded 2-3 times weekly to consume pills and/or selection bias of more compliant 
patients who volunteered for study participation. 
A number of factors have been reported to lead to the high rates of non-compliance 
observed in this population including: water intake restrictions, pill taste, pill size, frequency of 
pill consumption, number of pills consumed, low income, low education, depression, cognitive 
impairment, recreational drug use, a poor social support system, poor satisfaction with care, and 
cultural beliefs [201, 202].  In addition, the more pills patients consume daily, the lower the 
compliance [203].  Therefore, attempts to reduce pill burden are needed to increase pill 
compliance in this population.  Phosphorus binders represent approximately one-half of total 
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daily pill intake in MHD patients [199] and could be reduced through dietary modification.  
Dietary phosphorus is classified as organic, found animal and plant sources, or inorganic, added 
to foods to increase shelf-life and palatability [204].  Organic phosphorus from animal and plant 
sources is absorbed at a rate of 40-60 and 20-40 percent, respectively, while inorganic 
phosphorus is absorbed at a rate of 100 percent.  Therefore, inorganic phosphorus has a 
significantly larger effect of blood phosphorus levels and is a potential target for dietary 
intervention.  Future studies are needed to determine if dietary interventions to reduce inorganic 
phosphorus intake reduce pill burden and increase pill compliance in MHD patients. 
In summary, 6 months of HMB supplementation did not result in any significant changes 
in body composition, strength, physical function, fall risk, or quality of life in this population in 
the intent-to-treat analysis.  A trend for an improvement in chair stand, up-and-go, and shoulder 
flexibility tests was observed in the per-protocol analysis.  However, the per-protocol analysis 
was underpowered due to low pill compliance in this population.  Future studies are needed to 
improve pill compliance and attenuate muscle and strength losses to improve quality of life in 
this critically ill patient population. 
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Conclusion 
 Six month of beta-hydroxy-beta-methylbutyrate (HMB) supplementation did not result in 
any significant changes in body composition, bone density, strength, physical function, fall risk, 
or quality of life in maintenance hemodialysis (MHD) patients in an adequately-powered intent-
to-treat analysis.  Upon analysis of plasma HMB concentrations, 31 percent of participants in the 
HMB group were found to be non-compliant, likely due to the large number of oral prescription 
medications MHD patients consume daily.  Therefore we performed a per-protocol analysis 
using only participants who were compliant throughout the study.  Similarly to intent-to-treat 
analysis, no significant effects of HMB supplementation on outcomes of interest were observed 
in the per-protocol analysis.  However, a trend for improvement in several markers of physical 
function was observed with HMB supplementation in per-protocol analysis, despite being 
underpowered.  Taken together, these results do not support the use of HMB attenuation of co-
morbid disease conditions in MHD patients; however, future studies are needed to reduce pill 
burden and improve pill compliance in this population. 
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